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CATHEPSIN K TARGETING MATRIX REGENERATIVE NANOPARTICLES 
FOR SMALL ABDOMINAL AORTIC ANEURYSM REPAIR 
JONATHAN M. FOX 
ABSTRACT 
 
Abdominal aortic aneurysms (AAAs) are characterized by the loss of elasticity in 
the aorta wall leading to a chronic increase in diameter and resulting in rupture.  This is 
due to the lack of regeneration of elastic fibers and chronic proteolytic breakdown of elastic 
fibers within the aorta mediated by matrix metalloproteinases (MMPs), specifically MMP-
2 and -9.  Previous studies in our lab have shown cationic amphiphile-surface 
functionalized poly(lactic-co-glycolic acid) (PLGA) nanoparticles (NPs) loaded with 
doxycycline (DOX) to inhibit MMP activity and stimulate elastic matrix synthesis, effects 
we attributed to both low doses (< 10 mg/ml) of DOX released and independent effects of 
cationic amphiphile pendant groups on the NP surface.  This promises application of these 
NPs to arrest or regress AAA growth since high oral DOX dosing inhibits new elastic 
matrix formation in the AAA wall and has undesirable side effects.  In this study, we 
investigated feasibility of antibody-based active targeting of intravenously infused NPs to 
the AAA wall.  Cathepsin K, a cysteine protease, is a biomarker for AAA and 
overexpressed in abdominal aortic aneurysm tissue making it an ideal target moiety.  We 
have shown using a covalent conjugation method of modifying the surface of the NPs with 
a cathepsin K antibody resulted in a more robust antibody attachment which did not affect 
the DOX release profile.  Cathepsin K expression was confirmed to be localized on the cell 
surface and utilizing cathepsin K Ab-conjugated NPs, we demonstrated an increased NP 
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localization to the cathepsin K overexpressing cells in vitro and ex vivo.  Importantly, the 
DOX-loaded NPs demonstrated pro-elastogenic and anti-proteolytic effects in aneurysmal 
smooth muscle cells supporting their use as regenerative therapies to arrest and regress 
AAA growth.  Preliminary data has been collected indicating cathepsin K Ab-conjugated 
NP targeting to AAAs in elastase-injured rat models.  The study outcomes support the 
feasibility of using cathepsin K Ab-conjugated NPs as a targeted therapy for elastic matrix 
regeneration in AAA tissue and will serve as a basis for already initiated follow up studies 
to assess NP biodistribution, in situ retention in the AAA wall, and safety as a function of 
time.   
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CHAPTER I 
INTRODUCTION 
 
1.1. Cardiovascular disease and abdominal aortic aneurysms 
 
 Cardiovascular disease (CVD) broadly describes a variety of disease states 
including coronary artery disease, myocardial infarction, heart failure, and aneurysms1.  
Currently, CVD is the leading cause of death in the United States, with approximately one-
third of the population living with at least one type of CVD, and one of the most prominent 
causes of death worldwide1–3.  CVD is becoming more prevalent in the US, and currently 
accounts for ~17% of the healthcare expenditures with the medical costs increasing by ~6% 
annually2.  In 2010, it was estimated $444 billion was spent on treatment and medications 
for CVD and associated lost productivity, while hospitalization costs reached an additional 
$33 billion3.  With increased prevalence and cost associated with CVD, treatment options 
and preventative measures are becoming areas of much interest4. 
Abdominal aortic aneurysms (AAAs) are a prominent manifestation of CVD.  They 
are abnormal and rupture-prone expansions of the wall of the abdominal aorta segment 
(Figure 1.1).   AAAs occur in approximately 6-7.6% of men and 0.7-1.3% of women 
(increases to 6% when multiple risk factors present) in the US, and account for more than 
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13,000 deaths per year domestically5–7.  While certain sub-populations (elderly males, 
Caucasians, and smokers) have been identified to be more susceptible to developing AAAs, 
screening these individuals at an early stage in AAA development is vital.  Currently, the 
United States Preventive Task Force recommends men between the ages of 65 to 75 
undergo a one-time ultrasound screening to detect and thus initiate early management of 
AAAs8.  If unchecked, the mortality rate after AAA rupture is ~80% and 50% for those 
who receive emergency reparative surgery5,9.  This data emphasizes the importance of early 
diagnosis, identification, and treatment of AAAs, especially since this can improve survival 
and can be a cost-effective preventative measure.  
 
Figure 1.1. CT scan of an AAA in a 76-year old asymptomatic male5.  Adapted by 
permission from Macmillan Publishers Ltd: [NATURE REVIEWS CARDIOLOGY], 
Pathophysiology and epidemiology of abdominal aortic aneurysms. Copyright 1 Feb 2011  
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 Risk factors that have been associated with the formation and growth of AAAs 
include age, sex, family history, smoking, lipid levels, hypertension and obesity5,10.  The 
risk of AAA formation increases with age with individuals in the >50 year old segment 
being especially prone to developing AAAs.  AAA rupture is rare below 65 years of age 
but the risk increases by 40% for every 5 years after the age of 655.  Men are at a 6-fold 
higher risk for AAA formation than are women but the AAA development in women is 
highly correlated to family history suggesting that genetics also play a vital role in disease 
etiology6.  Patients with a positive family history were found to exhibit twice the risk of 
AAA formation than someone without a family history5.   
 The formation and growth of an AAA is a very slow process, extending over 5-7 
years and results from the loss of the structural extracellular matrix (ECM; stretch and 
recoil generating elastic fibers and collagen fibers that impart stiffness and load bearing 
strength)11,12 in the wall of the aorta due to chronically overexpressed matrix 
metalloproteinase (MMP) enzymes and cysteine proteases13–16. AAA growth is generally 
seen as irreversible or even difficult to arrest due to poor auto-regeneration and repair of 
elastic matrix structures in adult tissues, and lack of technologies to overcome these 
issues17.   
1.2. Current methods to diagnose and treat AAAs 
 
 Since AAAs are typically asymptomatic until they attain a critical size (> 5.5cm in 
diameter versus a normal aorta with a diameter of 2-2.5 cm), their detection tends to mostly 
coincide with elective imaging-based screening of high risk patients with known risk 
factors for AAA formation (e.g. elderly Caucasian males and smokers)9.  The World Health 
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Organization (WHO) has developed protocols and guidelines to determine the 
effectiveness and usefulness of screening tests for specific diseases.  Based on the criteria 
set by the WHO, AAAs can be considered a screenable disease which will help increase 
survival rates9. 
 Among other techniques, ultrasound has been utilized to successfully detect 
aneurysmal expansions.  Ultrasound technology can clarify the diameter of the aneurysm, 
an important factor in determining the future treatment course9. The screening method has 
proven to be an effective tool in reducing rupture and increase survival rates with studies 
showing screening processes can reduce the rate of rupture by 55-70% over a five year 
period9.    Current management of AAAs smaller than a critical size of 5.5 cm is limited to 
such passive ultrasound based growth monitoring, conducted every 6 months. If the 
aneurysm is close to 5 cm in diameter, or if the annual growth rate exceeds 10%, active 
treatment may be mandated, since significant increases in risk of AAA rupture are 
indicated10.  At this time, active treatment of large, critically-sized AAAs is primarily via 
surgical intervention (Figure 1.2).  
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Figure 1.2. Current treatment options based on AAA size and patient history. 
 
  In the open repair procedure18, the aneurysmal vessel segment is surgically excised 
and replaced with a graft. In the minimally invasive endovascular repair (EVAR) 
procedure, the aorta is opened lengthwise and a stent inserted within.  Once the stent has 
been inserted, both ends of the stent are sutured to the aortic wall such that blood does not 
leak out.  Once the stent is attached to the aorta, the aortic wall is closed around the stent 
and sutured back together18,19.  Despite being applied to large rupture prone AAAs, surgery 
on small (<5.5 cm diameter) AAAs is elective, and performed in only ~35% of small 
AAAs20. Such elective surgical intervention has been found to provide no benefit in terms 
of preventing continued AAA growth to rupture or improving post-op patient survival. The 
procedural risk of surgery on small AAAs also greatly exceeds their rupture risk (~2% for 
aneurysms less than 4 cm)20. Since no other clinically proven drug-based treatments exist 
for small AAAs, management of small AAAs, as mentioned above, is currently limited to 
passive, imaging-based growth monitoring leading to a pre-rupture stage when surgery is 
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inevitable. Given the slow growth of AAAs to rupture, which occurs over a 5-7 year period, 
there is a long-window of opportunity to deliver therapies targeting arrest or reversal of 
AAA growth.   
  Although there are several drugs in the discovery pipeline for the treatment of 
AAAs, treatment of AAAs with doxycycline (DOX), a modified tetracycline with 
antibiotic properties has been most promising.  Studies have shown DOX to attenuate 
MMP activity in the AAA wall to slow proteolytic disruption of the aortic wall ECM17,21, 
towards slowing AAA growth.  However, most of these outcomes have been observed in 
animal models18,19 and clinical outcomes are inconsistent5. There are also other critical 
challenges with DOX therapy including a) systemic inhibition of MMPs, which play 
essential roles in healthy tissue remodeling and maintenance, b) several body-wide side 
effects, and c) inhibitory effects of DOX at these high oral doses, on the already poor 
deposition of new, crosslinked elastic matrix in the AAA wall22. Since restoring elastic 
matrix homeostasis is essential to arrest or reverse AAA growth, oral DOX therapy has 
poor prospects to achieve these outcomes. Recent findings in our laboratory have shown 
for the first time that DOX at low micromolar doses maintains its anti-MMP effects but 
additionally, also provides pro-elastogenic properties23. On the basis of this evidence, and 
considering the deficiencies of oral DOX dosing, there is a significant motivation for AAA 
tissue-localized, predictable and sustained low level DOX dosing. Nanoparticles (NPs) 
may be useful vehicles for such localized drug therapy. 
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1.3. Nanoparticles and their use as a targeted treatment option 
 
  The term nanoparticle can be used to describe an object in the size range of 
approximately 1 to 100 nm in all three dimensions while other definitions suggest the range 
is from 5 to 200 nm or even as large as 1 µm24–26 (Figure 1.3).  However, the definition of 
a nanoparticle is not necessarily determined by its size but rather by its physical properties.  
A particle could be considered a nanoparticle if its properties are different than the 
properties of the bulk material of the same substance24.   
 
Figure 1.3.  Sizes of common pharmaceutical treatments24. Reprinted from Chemical 
Engineering Science, 125, Byung Kook Lee, Yeon Hee Yun, Kinam Park. Smart 
Nanoparticles for drug delivery: Boundaries and opportunities, 158-164., Copyright 2015, 
with permission from Elsevier. 
 
  Encapsulating the drug within the nanoparticle provides opportunities to enable 
controlled (e.g., steady-state), predictable, and sustained release of the drug, protect the 
drug from rapid degradation and thus extend its half-life in vivo, permit low level dosing 
of active agent with reduced systemic biodistribution and effect, and provide a much lower 
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footprint in terms of vehicle degradation byproducts and associated toxicity27–29.  NPs thus 
have attractive prospects to improve efficacy of drug-based treatments30.   
Our lab has recently designed biodegradable polylactic co-glycolic acid(PLGA)- 
polyethylene glycol (PEG) NPs for sustained (>6 months), predictable, and steady release 
of DOX locally within the AAA wall at very low doses (i.e., 1/100th of the useful oral dose 
or 1-20 g/ml) at which we found DOX to continue to inhibit MMPs but, in addition, also 
stimulate elastogenesis23. A unique feature of the NP design is the incorporation of pendant 
cationic amphiphile functional groups on the NP surface that augment elastin regenerative 
repair by a) enabling NPs to hydrophobically interact and bind to the exposed elastin core 
of disrupted elastic fibers at the site of tissue repair, b) stimulating elastin precursor 
synthesis, crosslinking and fiber formation by aneurysmal SMCs, and c) inactivating 
elastolytic MMPs23. Through the independent but synergistic effects of the functionalized 
PLGA nanocarriers and their released drug (DOX), the DOX-NPs are able to shift the 
balance between elastic matrix biosynthesis (elastogenesis) and elastin breakdown 
(elastolysis) to facilitate robust and lasting buildup of stable and mature elastic fibers at the 
AAA tissue site. Despite these highly promising outcomes, further innovation in NP design 
is required to actively target these NPs in an efficient manner to the AAA wall following 
simple intravenous (IV) infusion.  The focus of this thesis is to explore one such antibody-
based active targeting strategy.  
1.4. Problem statement and thesis objectives 
 
 The objective of this thesis is to develop an antibody-based modality for active 
targeting and improved retention of our DOX loaded, anti-proteolytic, and pro-matrix 
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regenerative NPs to/within the matrix-disrupted AAA wall, without adversely 
compromising their functional effects. Potential NP targets are cysteine proteases 
overexpressed in AAA tissue.  Of particular interest within the family of cysteine proteases 
is the group of enzymes termed cathepsins.  These proteins have been associated with many 
physiological processes including cartilage proteoglycan degradation, ECM regeneration 
and embryonic development13.   The cathepsin family includes enzymes that target both 
elastin (elastases) and collagen (collagenases); these include cathepsin S (cat S), cathepsin 
K (cat K), cathepsin L (cat L), and cathepsin V (cat V).  Even though cathepsins have been 
associated with a wide range of physiological processes, overexpression of cathepsins has 
only been recently linked to formation and growth of AAAs14,16.  While the role cathepsins 
play in AAA formation is still not completely understood, their high level of expression 
both in AAA tissues and in serum/plasma of AAA patients, makes them a useful biomarker 
for early diagnosis of AAA formation, growth assessment, and a potential target for drug 
delivery to the AAA wall16.   
 The specific aims of this study are: 
1. To determine if functionalization of the NP surface with a cathepsin K 
antibody improves their targeting and uptake to the AAA wall without 
change in their physical and functional pro-regenerative/anti-proteolytic 
properties in vitro and in ex vivo culture models.   
2. To assess trans-endothelial migration of Ab-functionalized NPs from the 
lumen to the AAA wall and benefits of αvβ3-integrin antibody tagging for 
this purpose.  
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3. To generate initial evidence of successful delivery of the cathepsin K Ab-
modified NPs to AAAs in a rat model following intravenous infusion. 
 
1.5. Organization of thesis 
 
Chapter 2 presents an extensive literature review to provide background on the 
structure of vasculature, abdominal aortic aneurysm etiology and progression, a detailed 
explanation of current treatment options for AAAs and their limitations, nanoparticle uses 
in various treatments and how to apply nanoparticles to the treatment of AAAs.  Chapter 3 
presents comprehensive experimental methods used for in vitro and in vivo treatment with 
antibody-modified NPs.  Chapter 4 outlines and interprets the results and provides 
interpretations of these results.  Chapter 5 explains the limitations and future work to 
further advance the use of antibody modified nanoparticles in the treatment of AAAs.   
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CHAPTER II 
BACKGROUND 
 
2.1. Vascular physiology 
 
 The vascular system is a complex network of blood vessels that delivers oxygenated 
blood from the heart to tissues in the body to support their proper function.  Arteries are 
exposed to drastic increases in blood pressure following each ventricular contraction.  They 
respond by expanding with increased pressure and relaxing with decreased pressure to 
propel blood forward between heartbeats.  Expansion of the major vascular conduit leading 
from the heart, the aorta, controls the pressure spike from each heart contraction and evens 
out the blood flow in smaller vessels31.  In cross-section, the walls of blood vessels are 
composed of three major layers – the tunica intima, the tunica media, and the tunica 
adventitia (Figure 2.1).  These layers have distinct cell types and extracellular matrix 
(ECM) composition that allows them to perform specific functions and change under 
certain physiologic conditions.  The demand for blood and nutrients varies widely between 
tissues but can rapidly change in the same tissue under different environmental conditions.  
The vascular system is well adapted to meet these varying demands and arteries play a key 
role in controlling blood flow31.   
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Figure 2.1. The artery is composed of three separate layers all with different compositions 
and functions32,33.  Adapted from Encyclopedia Britannica Online.  
 
2.1.1. Tunica Intima  
 
 The tunica intima is the innermost layer of the blood vessel, adjoining the lumen, 
and consists of endothelial cells (ECs) and the subendothelial matrix34.  The subendothelial 
layer consists of a specialized ECM or basement membrane comprised of collagen type IV, 
laminin and proteoglycans35.  In the artery wall, the monolayer of ECs respond to increased 
fluid shear stress due to blood flow by releasing specific factors such as nitric oxide or 
prostacyclin that incite relaxation of smooth muscle cells (SMCs) surrounding the intima 
layer31.   
The role of endothelial cells in the tunica intima is to serve as a barrier, affect 
vasodilation, and influence thrombotic events.  The ECs act as a selective barrier by 
controlling the passage of particles into and out of the bloodstream.  The control of particle 
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passage is due to the ECs ability to change the adherens and tight junction complexes 
between cells36–38.  Beyond their role as a barrier, ECs play a role in responses to tissue 
damage as well as an anti-thrombotic function to prevent thrombosis and blockage of the 
artery36,39.  The release of adhesion molecules and cytokines into the blood stream recruit 
leukocytes to repair tissue damage.  To regulate thrombotic events in the blood vessel, the 
ECs release various molecules to inhibit or promote the activation of platelets and the 
coagulation cascade36.  Besides the release of molecules that regulate coagulation, ECs 
release various factors to control vasodilation40.  The endothelium releases factors such as 
nitric oxide (NO) and prostacyclin (PGI2) to induce dilation of the artery or thromboxane 
(TXA2) and endothelin-1 (ET-1) to cause constriction.  The vasoactive factors released by 
the ECs target the smooth muscle cells in the tunica media to change the vessel diameter40. 
2.1.2. Tunica Media 
 
 The tunica media, the middle layer of the artery, is mostly comprised of vascular 
smooth muscle cells (SMCs) surrounded by another basement membrane and ranges in 
thickness from 0.03 mm in mice to 1.12 mm in humans35,41.  In the tunica media of the 
aorta, elastin and collagen are precisely oriented forming defined layers.  The layers of 
thick elastin, termed lamellae, are seen as concentric plates with thin elastin fibers 
connecting the elastin layers.  Between the layers, collagen is present and aligned 
circumferentially and while the elastin fibers are connected, there are no connections 
between the collagen and elastin41.  This arrangement of elastin and collagen could present 
a challenge in regeneration of the vascular wall especially concerning the crosslinking of 
elastin and not of collagen.  The SMCs are located between the elastin lamellae and the 
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interactions between cells, elastin and collagen produce the viscoelastic properties of the 
aorta41.   
The SMCs in the arteries respond to changes in blood pressure through the 
myogenic effect.  In response to elevated pressure, the SMCs contract narrowing the artery 
while maintaining a constant blood flow downstream.  Chronic high pressure in the arteries 
causes the SMCs to remodel the vascular wall by increasing its thickness helping to resist 
pressure.  However, this remodeling can disrupt the elastic matrix and decrease the 
capability to withstand sudden pressure changes31.  Disruption of the elastin in the artery 
wall can alter the SMC phenotype and generate a cascade of problems for the ECM.  SMCs 
remain in a quiescent contractile state in mature arteries but can differentiate under certain 
conditions such as injury or repair42.  In vitro experiments confirmed the role of elastin in 
regulating SMC proliferation, migration and differentiation.  Elastin significantly inhibits 
SMC proliferation and migration while maintaining the contractile phenotype42,43.  Results 
from several studies have determined elastin is not only vital for artery recoil but plays a 
regulatory function through SMC proliferation42,43.   
2.1.3. Tunica Adventitia  
 
 The tunica adventitia, the outermost layer of the artery, composed of connective 
tissue, small blood vessels and nerve endings is a structural support for the tunica media44.  
While the main function of the adventitia was considered to be support, it is now 
understood to play an important physiological role in vascular function.  In diseases where 
vascular function has been affected, noticeable changes in structure and biochemical 
composition are observed.  Removal of the adventitia from rat carotid arteries decreases 
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contractile capabilities and increases the endothelium function suggesting its role in 
vascular function44.  Even though the adventitia surrounds the artery it can affect other 
layers.  Adventitial fibroblasts may be substitutes for the endothelial cells in regulating 
artery tone or the source for proliferating cells in the intima caused by atherosclerosis45.  
Overall, the tunica adventitia plays a role in vascular function beyond its structural support 
of the tunica media.  
2.2. Composition and structure of the extracellular matrix (ECM) 
 
 The ECM of the aorta wall plays a major role in determining its mechanics and 
regulating biology of the contractive vascular cells.  The ECM is comprised of several 
protein components which vary between the different tunic layers.  The two major 
structural components of the ECM of the vessel wall are collagen and elastin34.  The 
integrity of the ECM is maintained by contacting vascular cells (smooth muscle cells, 
fibroblasts) which are capable of limited matrix remolding.   
Both collagen and elastin play a vital role in determining vascular mechanics.  
Elastin is responsible for the initial change in modulus when the vessel undergoes 
expansion at physiologic pressures.  The elastic lamellae expand during increased pressure 
because of their low stiffness compared to collagen.  However, under increasing strain the 
modulus increases due to the collagen fibers.  At super-physiologic pressures, the collagen 
fibers begin to carry the load under the strain in order to maintain the aorta shape46,47.  
Eventually, the strain in the wall will become greater than the collagen strength and the 
wall will rupture.  Under diseased conditions, the mechanics of the wall are altered so lower 
strain can cause greater strains leading to increased stiffness (Figure 2.2)46. 
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Figure 2.2.  The stress-strain curve of a healthy and disease-simulated aorta46.  The normal 
aorta can withstand greater strains than the injured aorta. Reprinted from Ultrasonics, 50, 
Asawinee Danpinid, Jianwen Luo, Jonathan Vappou, Pradit Terdtoon, Elisa E. Konofagou, 
In vivo characterization of the aortic wall stress-strain relationship, 654-665, Copyright 
2010, with permission from Elsevier. 
  
2.2.1. Collagen 
 
 Collagen is one of the most abundant proteins in the ECM of connective tissues.  
There are as many as 16 different types of collagen but three types – I, II, and III – make 
up more than 80 percent of the collagen in the body48.  Collagen was thought to be only 
secreted by fibroblasts but now it is well understood that numerous cell types generate 
different collagen structures and this may play an important role in regeneration of the 
collagen matrix.  This is noticed in the varying deposition of collagen types in the different 
tunics and in arteries of different sizes.  Collagen is found in the tunica intima and 
adventitia but is limited in the medial layer.  However, no matter the structure and type of 
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collagen, the function remains the same, that is to help tissues withstand stretching forces 
to prevent their rupture.   
 Collagen, similar to many other secreted proteins, is synthesized as precursor 
molecules.  These chains are transported to the rough endoplasmic reticulum and undergo 
processing leading to formation and alignment of disulfide bonds between the precursor 
molecules to generate a triple helix structure48.  This triple helix conformation domain and 
the interactions between these domains help stabilize these aggregates to form larger 
networks.  The triple helix of collagen is characterized by the interweaving of three helical 
polypeptide chains.  This forms a coiled coil structure where, due to steric reasons, the 
center of the helix is comprised of only glycine (Gly) residues.  The amino acid sequence 
of these helices follows a similar pattern of Gly-X-Y allowing for the Gly to remain in the 
center of the helix.  Glycine is found in the center of the helix due to the single hydrogen 
atom while the other two amino acids provide stability.  Any other sequence of amino acids 
would disrupt the triple helix formation 49.   
After secretion of this triple helical structure into the extracellular space, both 
terminal regions of the propeptide are removed allowing the collagen to polymerize into 
fibrils48.  As mentioned before, the interactions of the helix domains stabilize the 
aggregates and this is due to the side chains of the X-Y amino acids in the polypeptide.  
The side chains of the X and Y amino acids are facing outside of the helix allowing for 
lateral interactions mediated by the crosslinking enzyme lysyl oxidase (LOX) (Figure 
2.3)48–50.  The crosslinks occur between helices and are critical for collagen function and 
strength.  The various collagen types allow collagen to generate a wide range of structures.   
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Figure 2.3.  Synthesis of collagen fibers50.  Collagen monomers can aggregate to form 
several types of structures with various mechanical properties49.  Adapted from Shoulders 
and Raines. Annu. Rev. Biochem. (2009). 78: 929-58.   
 
2.2.2. Elastin 
 
 Elastin is a key protein component of the elastic matrix which provides stretch and 
recoil properties to the vessel wall to accommodate blood flow during systole and to 
maintain blood pressure during diastole 42,51.  In the major arteries such as the aorta, elastin 
comprises ~50% of the tissue dry weight.  In the aorta wall, elastin is found mainly in the 
tunica media and is responsible for artery recoil.  Artery recoil was attributed to SMCs and 
elastin but comparing recoil of arteries with and without smooth muscle cells have shown 
similar recoil properties.  This suggests the cells do not play a major role in the contraction 
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of the artery after expansion but rather elastic fibers are the major contributor.  This is 
further confirmed in cases of mutations of the elastin gene (e.g., supravalvular aortic 
stenosis, cutis laxa, Williams Syndrome)52–54.  The mutations in the elastin gene causes 
loss of function or complete gene deletion.  In these mutations, the elastic lamellae in the 
aorta wall are fewer or disrupted leading to various degenerative vascular conditions and 
early mortality52.  
 The elastic matrix is generated through the crosslinking of tropoelastin monomers 
but the process is complex (Figure 2.4).  The elastic fiber is made of two distinct 
components, the microfibrils and an amorphous elastin core.  The amorphous elastin core 
is synthesized from tropoelastin monomers encoded by an ELN gene expressed by 
fibroblasts, smooth muscle cells, and endothelial cells during childhood but expression 
quickly decreases during adulthood51.  The tropoelastin monomers bind to the elastin-
binding protein which protects the monomers from degradation and phase separation while 
transporting the monomers to the cell surface55,56.  Once the complex is secreted from the 
cell, the elastin-binding protein interacts with other complexes causing the release of 
tropoelastin.  The elastin-binding protein returns to the intracellular space to bind more 
tropoelastin monomers and repeat the process51.  Outside of the cell, the hydrophobic 
domains of tropoelastin interact generating aggregates on the cell surface.  While this 
appears to be the beginning of the elastic fiber formation, studies have shown the 
interaction of the C-terminal of tropoelastin with microfibrils is the first step and is required 
to assemble an elastic fiber51.  Eventually, tropoelastin production and crosslinking at the 
cell surface generates a sufficiently sized aggregate and it is released from the cell surface 
where it migrates through the extracellular matrix and deposits into the microfibril 
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scaffold56.  Lysyl Oxidase (LOX) plays an important role in the crosslinking of tropoelastin 
leading to stable and non-reducible crosslinks34,57.  Once tropoelastin has been crosslinked, 
its production is reduced and there is minimal turnover of the mature elastin55.   
Figure 2.4.  Schematic showing steps in elastic fiber assembly. (1) The tropoelastin is 
secreted to the cell surface and binds to the Elastin-Binding Protein (2) before being 
polymerized (3) and released.  The tropoelastin undergoes cross-linking by lysyl oxidase 
(4) and is directed to assembly onto microfibrils (5) followed by aggregation and fiber 
extension (6) resulting in an aligned fiber (7). 
 
 As mentioned earlier, elastic fiber formation requires microfibrils and the 
microfibrils act as a scaffold and support elastin deposition.  The microfibrils are composed 
of fibrillin, specifically fibrillin-1, which is expressed across all tissues.  Fibrillin-1 is 
secreted and undergoes a cleavage step required for the multimerization to create structures 
at the cell surface.  Microfibrils are stabilized by a fibronectin network that promotes 
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interactions with other microfibril proteins where the microfibrils will be crosslinked 
leading to further stabilization of the structure51.  The aggregates associated with the 
microfibril continue to crosslink leading to larger aggregates generating a functional fiber.  
LOX, an oxidative deaminase, and Cu2+-dependent enzyme, oxidizes the deposited elastin 
until the coacervates coalesce and integrate onto the microfibril scaffold51.   
Elastin production is significant during prenatal and neonatal development but 
decreases by adolescence.  Fortunately, the half-life of cross-linked elastic matrix is ~74 
years so once the matrix has been deposited in childhood, it withstands an entire lifetime.  
This long half-life is due to the high degree of crosslinking and tightly packed nature of 
elastin due to its hydrophobicity.  Since elastin production is limited in adult SMCs and 
there are no current treatments to increase elastin production, disorders wherein accelerated 
enzymatic disruption of the elastic matrix occurs are difficult to treat or reverse33.  
However, the advances in tissue engineering and regenerative medicine may soon make it 
possible to stimulate elastin regeneration and repair such scenarios.      
 The tertiary structure of elastin varies across tissue types and this is due to the forces 
the tissue experiences.  The ELN primary transcript is heavily spliced causing isoforms 
that range from 60 to 75 kDa.  Six exons of human tropoelastin have been identified to be 
alternatively spliced affecting the hydrophobic and hydrophilic domains.  The splicing may 
be tissue dependent as multiple isoforms have been identified in aorta and lungs56.  The 
different splicing of domains may explain the differences in elastin structure in tissues.  For 
example, the aorta in humans may have as many as seven isoforms of elastin and this could 
affect the elastin structure56.  In the medial layer of the aorta, the elastin is arranged in 
concentric fenestrated lamellae while in elastic cartilage the elastin is configured in three-
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dimensional honeycomb-like structures and this could be the result of splicing51.  
Differently, in aortic valves, elastin is present as continuous and fenestrated sheets in the 
ventricularis layer and is found as discrete/loose fiber networks in the skin58.  The structure 
and content of elastin in various tissues are listed in Table 2.1.   
 
Figure 2.5. SEM images of bovine elastin fibers treated with cathepsin K.  Panel A shows 
untreated elastin with visible fibers.  Panel B shows elastin treated with cathepsin K in 
which disruption is visible.  Panel C, D, and E highlight the elastin treatment with a mutant 
cathepsin K to highlight exosite importance in degradation59. Adapted from Sharma et al. 
Biochem J. (2015), 163-173.   
 
Table 2.1. Elastic Fibers in Various Tissues and Elastin Content as Percentage of Dry 
Weight51. 
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 Mature elastin is stable under normal physiological conditions and exhibits minimal 
remodeling and turnover.  However, specific cell types (e.g., SMCs, fibroblasts) express 
elastin degrading enzymes (proteases, elastin matrix metalloproteinases, cysteine 
cathepsins) at low levels14,60,61.  Figure 2.5 highlights the degradation of elastin due to 
cathepsin K.  Figure 2.5.A shows the untreated elastin fibers in bovine.  Figure 2.5.B 
shows the disrupted elastin fibers following treatment with cathepsin K.  Figure 2.5.C, 
Figure 2.5.D, and Figure 2.5.E were treated with mutant variants of cathepsin K to 
highlight the importance of the exosites in the degradation of elastin59.  Such basal 
expression of elastin degrading enzymes is required for cells to migrate through the ECM.  
However, under certain diseased conditions or following tissue injury, these enzymes are 
expressed at greater levels leading to rapid elastic matrix degradation.  These elastases are 
generally released by recruited inflammatory cells and cytokine-activated fibroblasts in the 
vessel wall in several diseases (atherosclerosis, abdominal aortic aneurysms)55.   
2.2.3. Cathepsins 
 
 The extracellular matrix is a complex structure that continually undergoes 
remodeling and modification.  The restructuring of the ECM can be caused through 
enzymatic or non-enzymatic processes62.  The enzymatic processes were thought to be 
controlled by MMPs and serine proteases until recent discoveries have shown cysteine 
cathepsins also contribute to the degradation of the ECM.  Cysteine cathepsins were 
originally described as intracellular proteases requiring an acidic environment for optimal 
activity but under certain conditions, the cathepsins are secreted into the extracellular 
matrix and maintain their protease activity12,62.   
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 Cysteine cathepsins fall under a more diverse cathepsin group composed of various 
catalytic proteases.  The broad cathepsin group includes serine cathepsins, aspartic 
cathepsins and cysteine cathepsins.  Sequencing of the human genome has revealed 11 
cysteine cathepsins, the most abundant in the cathepsin group62.  Cathepsins are expressed 
in an inactive state and following transport to the lysosome are activated by removal of the 
predomain which can be autocatalytic or catalyzed by other proteases.  One important 
factor in autocatalytic activation is the presence of negatively charged surfaces that induces 
a conformational change allowing for processing by other proteases62,63.  The presence of 
a negatively charged surface such as an appropriately modified nanoparticle surface, could 
increase cathepsin activation so it is necessary to design their surface characteristics to 
achieve desired anti-proteolytic and pro-matrix properties for therapy.    
Cysteine cathepsin structure consists of two domains: a left domain composed of 
three α-helices and a right domain composed of a β-barrel.  Located between these two 
domains is the active site, a cysteine and histidine residue62,64.  Substrates bind to the 
cathepsin through interactions with both domains and along the active site cleft.  The 
binding of cysteine cathepsins and substrates exhibit a greater specificity compared to other 
cysteine proteases and this is attributed to the interaction of multiple binding sites.  
Specifically, cathepsin K exhibits specificity for proline and glycine residues and this 
matches the cathepsin K specificity for ECM proteins62.  The role of cathepsin K on the 
degradation of the ECM proteins will be discussed later.     
 The localization of cathepsins in lysosomes was thought to retain the cathepsins as 
intracellular proteases but they can be released into the cytosol and translocate to the cell 
surface or are secreted into the extracellular space.  Once in the extracellular space, cysteine 
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cathepsins degrade proteoglycans and fibrous proteins such as collagen and elastin (Table 
2.2).  Several proteases have been identified that degrade collagen including MMPs and 
cysteine cathepsin K65.  The degradation of collagen was thought to be originally caused 
by multiple cysteine cathepsins until recently when cathepsin K was shown to be the only 
physiologically relevant collagenase.  While other collagenases (MMPs, elastase) cleave 
the triple helix in collagen at a single site, cathepsin K can cleave the helix in multiple sites 
as well as cleave the telopeptide region producing collagen monomers making cathepsin K 
more potent62,65.  Another important component of the ECM, elastin, can be degraded by 
cathepsin K - known to be a potent elastase.  Cathepsin K contains two hydrophobic 
exosites which play a major role in stabilizing the interactions between elastin and 
cathepsin K.  The structure of cathepsin K makes it a potent elastase due to the exosites 
being located far from the active site and the binding of elastin to these sites positions the 
cleavage susceptible region of elastin in the cathepsin active site62.    
Table 2.2.  Cysteine cathepsins and their extracellular matrix substrates62. 
 
 
 Cathepsin K plays a crucial role in the degradation of collagen and elastin and this 
has an impact on vascular diseases.  Vascular diseases, such as atherosclerotic plaque and 
atheroma, have shown significantly increased cathepsin K expression14.  This is significant 
because atheroma is associated with regions of increased elastin degradation.  Beyond their 
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role in atherosclerosis and degradation of the ECM, cathepsins play an important role in 
immune response.  One such disorder, where the breakdown of elastin and immune 
response lead to disease progression, is an abdominal aortic aneurysm (AAA) in which 
cathepsin K contributes to AAA formation and growth12,62.  The role of cathepsin K in 
AAA progression was confirmed using cathepsin K deficient mice.  In these mice, the aorta 
was infused with elastase to induce an aneurysm.  Compared to the control mice, the 
cathepsin K deficient mice were protected from AAA formation66.   
2.3. Abdominal aortic aneurysms (AAAs)  
 
 Abdominal aortic aneurysms are localized expansions of the aorta that develop and 
grow to rupture due to the chronic overexpression of matrix metalloproteinases causing 
irreversible breakdown of vessel wall elastic matrix.  Clinically, AAAs are defined as aortal 
expansions with a 50% increase over the healthy aortal diameter (2.5 cm)67.  Elderly male 
smokers are at the greatest risk for developing an AAA, however the prognosis for women 
is worse with a rupture rate 4 times greater68.  The formation of an aneurysm has been 
linked to genetic factors but environmental factors play a major role in development.  
2.3.1. AAA etiology 
 
 The formation of an AAA can be caused by multiple factors such as trauma, chronic 
hypertension, vasculitis or inflammatory diseases (e.g. atherosclerosis) but this accounts 
for a small portion of aneurysms.  Therefore, most aneurysms have been termed “non-
specific” but atherosclerosis has been associated with most cases of AAAs69.  However, 
this view on the development of the abdominal aortic aneurysm has been challenged but in 
all cases, there is an initial stimulus that induces AAA formation.  Figure 2.6 shows the 
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etiological progression for AAA development and growth to rupture.  An AAA occurs after 
an initial injury or stimulus causing the recruitment of inflammatory cells to the aortic wall 
(Figure 2.6.1 and Figure 2.6.2).  The inflammatory cells release proteases, specifically 
matrix metalloproteinases (MMPs) (Figure 2.6.3).  The proteases degrade the fibrillar 
collagens and elastic matrix generating elastin fragments69.  The elastin fragments have a 
two-fold effect.  First, the fragments recruit more inflammatory cells thereby creating a 
positive feedback loop.  The elastin fragments recruit leucocytes to the aortic wall as well 
as inflammatory cytokines, chemokines and prostaglandins69.  Additionally, the elastin 
fragments induce smooth muscle cell apoptosis which further results in decreased elastin 
content (Figure 2.6.4).  The SMCs express several ECM proteins and therefore are critical 
in vascular wall remodeling so the depletion of SMCs limits remodeling capabilities.  
Further, the loss of elastin content exposes the SMCs to an increased stress and to 
compensate, the cells produce additional collagen matrix (Figure 2.6.5).  The collagen in 
the tunica adventitia plays a critical role in the resistance to rupture once the elastin in the 
tunica media has been broken down69.  The increased collagen production leads to a 
transient wall thickening but is susceptible to proteolytic breakdown, eventually leading to 
wall thinning (Figure 2.6.6).  The stress in the aortic wall becomes greater than the wall 
strength and the aneurysm ruptures (Figure 2.6.7).   
28 
 
 
 
Figure 2.6.  Abdominal aortic aneurysm etiology in which an initial injury stimulus (1) 
begins aneurysm development and ends with wall thinning (7) and eventual aorta rupture.     
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The inflammatory cells recruited to the aneurysm site release proteases, specifically 
matrix metalloproteinases (MMPs).  As previously mentioned, aneurysms were thought to 
be caused by atherosclerotic disease but recently there has been a shift citing MMPs to play 
an important role in formation68.  The release of MMPs was originally thought to occur 
from the inflammatory cells recruited to the aneurysm site but experimental data has shown 
activated endothelial cells, aortic SMCs and adventitial fibroblasts are secreting MMPs 
into the ECM.  When MMPs are secreted into the ECM, they are in an inactive form and 
converted to an active form.  This may be a useful target for treating AAAs.  Inhibiting the 
activation of MMPs in the aneurysm tissue could significantly decrease growth and 
formation.  Specifically, MMP-9, expressed by macrophages in the aneurysm, has an 
affinity for the breakdown of elastin and collagen and the increase in aneurysm diameter 
may be correlated to its expression68.  Therefore, identifying inhibitors of MMPs may be a 
crucial part of aneurysm treatment.   
2.3.2. Treatment options for AAAs  
 
 Identification of high risk populations and preventative, imaging-based screening 
has enabled the detection of aneurysms early in development.  At the present time, 
management of small AAAs is limited to passive ultrasound or magnetic resonance 
imaging (MRI) every six months and endovascular/surgical repair at a critical size (>5.5 
cm) (Figure 2.7) when rupture risk greatly exceeds surgical risk10,20. Even with screening 
and treatments, AAA rupture still remains one of the largest causes of death in the elderly11.  
There are currently several treatments available for large AAAs to reduce the risk of rupture 
but the risks and benefits of repair need to be compared to the risk of rupture before elective 
surgery should be considered.  The two most common surgeries are endovascular stent 
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graft and open repair.  Each treatment has its advantages and limitations so careful 
consideration should be used when determining the appropriate course of treatment as one 
treatment may be better suited for some individuals.    Since current treatment options are 
limited to large AAAs, developing a novel treatment for small AAAs has several 
advantages.  Treatment of small aneurysms reduces the risks associated with surgeries 
especially in elderly patients and can reduce the costs of late intervention.  Arresting and 
regressing the aneurysm growth at an early stage can prevent future hospital visits.  Another 
advantage of treating small AAAs is the increase in quality of life.  With the current options 
of passive monitoring and no active treatment, the quality of life is decreased due to the 
waiting period for aneurysm growth.   
 
Figure 2.7. Current treatment options vary for small and large aneurysms due to the risk 
of rupture.  Small aneurysms are managed using passive imaged-based monitoring until 
the size and risk of rupture increases and surgery is performed.    
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2.3.2.1. Endovascular stent graft repair 
 
 Endovascular stent graft repair of AAAs is a common treatment option and a viable 
alternative to other surgical options as it is less invasive.  In endovascular aortic repair 
(EVAR), the aim is to reduce the risk of rupture by excluding the aneurysm sac from the 
circulation of blood (Figure 2.8).  Excluding the aneurysm sac is accomplished through 
the placement of a bypass graft in the aorta18,67.  Most abdominal aortic aneurysms (~70%) 
can be treated with endovascular repair due to their morphology but there are several 
limitations to this treatment.  If the patient is under 60 years of age, the use of a stent graft 
is not suggested since there is lack of long-term durability data.  Other limitations include 
a short, conical proximal neck or thrombus within the proximal neck18.  In EVAR, a 
catheter with the stent graft is inserted into the femoral artery and guided to the aneurysm.  
Once the stent graft is located at the aneurysm site, the graft is expanded and attached to 
the aorta wall.  The stent graft is checked with dye to ensure there is no blood leakage 
around the area.  The catheter is removed leaving the stent graft in place and the femoral 
artery site sutured together leaving only small incision sites70.      
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Figure 2.8. A 3-D reconstructed image of an AAA. The left image shows a 7.9 centimeter 
aneurysm and the image on the right shows the stent graft in place after surgery71.  
Reprinted from European Journal of Vascular and Endovascular Surgery, 52, C.V. 
Ioannou, D.K. Tsetis, Going Beyond Current AAA Neck Angulation Limitations of the 
Ovation Ultra-low Profile Polymer-filled Stent Graft, 172, 2016, with permission from 
Elsevier. 
 
 While minor complications can arise from surgery itself, once the endovascular 
graft has been surgically implanted complications caused by the stent can occur.  These 
complications include renal failure, endoleak, occlusion, migration or infection of the stent 
graft.  While only occurring in 1 to 3% of patients, bowel ischemia is a serious complication 
with a 50% mortality rate within 1 month72.  In bowel ischemia, thrombotic deposits can 
be dislodged while the stent is being positioned and can travel into the renal or lower-limb 
circulation resulting in patchy ischemia72.  Similar to bowel ischemia, renal artery 
occlusion is another complication that occurs in less than 5% of cases.  In renal artery 
occlusion, the stent covers the renal arteries preventing blood flow but if detected early 
enough the stent can be repositioned without any major side effects72.  While these 
complications are associated immediately after surgery, the most common complications 
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occur within a few months after the surgery.  Limb thrombosis can occur in as many as 
40% of cases with the underlying cause being stent-graft kinking72.   
2.3.2.2. Open aneurysm repair 
 
 Similar to endovascular stent graft repair, open repair utilizes a stent graft to remove 
the aneurysm sac from circulation, however the main difference is the delivery method of 
the stent.  In open aneurysm repair, an incision is made down the center of the abdomen to 
expose the aorta.  Once the aorta is exposed, it’s clamped above and below the aneurysm 
site to stop blood flow.  The aneurysm sac is cut open and a graft inserted.  The graft is 
sutured to the aorta wall effectively connecting the two together.  The clamps are removed, 
the aorta wall wrapped around the graft and sutured together before suturing the abdominal 
incision70.   
 The open repair procedure is more invasive than EVAR.  Although EVAR shows 
a lower 50-day mortality but the long term results of open repair may outweigh the risks73.  
Common complications are similar to EVAR with open repair including bleeding, small 
bowel obstruction, hernia and ischemia.  The complications were corrected through 
reintervention surgery and most reintervention surgeries were not related to the graft but 
were directly related to the laparotomy73.  However, patients undergoing EVAR had a 3-4 
times greater risk of graft related complications or reintervention compared to patients 
undergoing open repair.  EVAR carries an advantage in mortality after the first few years 
but that advantage disappears over time.  This may be due to the late rupture of patients 
treated by EVAR73.  While EVAR may have reduced initial risks, open repair requires less 
follow-up monitoring.  The open repair surgery is considered ‘for life’ and requires 
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minimal to no follow-up monitoring because there are so few late complications.  Finally, 
the reintervention rate for EVAR was 41% while the reintervention rate for open surgery 
was 9%73.  The long term complications and costs associated with open repair compared 
to EVAR require more data to decide which treatment option should be considered the 
standard73. 
2.4. Restoring elastin homeostasis in the AAA wall  
 
 The goal of tissue engineering and regenerative therapies is to utilize patient 
derived cells or other biological materials/resources to generate functional, structural and 
biological mimics of native tissues on demand to restore or replace diseased tissues. Tissue 
engineering of the aorta would be an exciting breakthrough in the treatment of AAAs and 
could become the standard treatment.  The extracellular matrix of the aorta is complex and 
requires significant remodeling to treat aneurysm formation so it is necessary to explore 
several tissue engineering options.   
 Current advances in restoring elastin include improvements in cell therapies and 
drug-based MMP inhibition.  The use of cell therapies provide unique treatment 
opportunities.  Autologous cell therapies reduce the likelihood of an immune response as 
the cells were taken from the patient but the applications of use for these cells can be 
limited.  Another possible cell therapy utilizes stem cells.  Stem cells can be generated from 
multiple sources and tailored to a specific application but can be severely limited in clinical 
settings.  To use stem cells in a clinical setting, the culture conditions and processes must 
be highly regulated to ensure there are no variations in the cell types and complications 
upon implantation.  Drug-based MMP inhibition is an attractive option for restoring elastin 
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because once the drug has been FDA approved it can be mass produced.  Unlike cell 
therapies, using drug-based therapies limits the time spent in hospitals since most drugs are 
administered at home.  However, the use of drug-based MMP inhibition has its drawbacks.  
MMP expression and activity is required as part of the natural remodeling within the body 
so the high concentrations of MMP inhibitors, especially from oral dosing, can have 
systemic side effects.    
2.4.1. Elastin regeneration using stem cells 
 
 Terminally-differentiated, healthy adult vascular SMCs are poorly elastogenic and 
thus cannot be used for cell therapy towards regenerative repair of AAAs.  However, a 
viable option to regenerate the elastic matrix is through the use of stem cells.  Elastin 
production is upregulated during fetal and transiently during vascular injury responses, 
both representing the only scenarios when this occurs.  However, the elastin produced by 
inflammatory cells fails to crosslink into elastic fibers74.  Stem cells and their SMC-like 
progenitors/derivatives are purported to play a key role in elastogenesis in such scenarios.  
For effective cell therapy, it is crucial to identify stem cells and derivative phenotypes that 
will stimulate the diseased SMCs to produce elastic matrix, inhibit matrix proteolysis, and 
also serve as an additional source of new elastic matrix to augment elastin regeneration at 
the AAA site.   
 There are several sources of adult stem cells available for cell therapy including 
those from bone marrow, peripheral blood, and adipose tissue.  The advantages of using 
these autologous stem cells is the lack of immune rejection.  These adult stem cells 
(mesenchymal stem cells or MSCs) are multipotent meaning they can differentiate into 
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several distinct cell lineages.  MSCs have been successfully differentiated into adipocytes, 
chondrocytes, osteocytes, and SMCs75–78.  They provide several advantages for cell 
therapies for matrix regeneration including their immunoregulatory property – which 
prevents activation of the immune response through inactivation of surface markers in T-
lymphocytes even upon allogeneic implantation79.  Multiple studies have suggested MSCs 
stimulate matrix regeneration and tissue recovery which may play a crucial role in treating 
AAAs.  One such study determined when rat aorta tissue from an AAA model was co-
cultured with MSCs, there was an increase in elastin fiber formation compared to controls.  
Another study found when the MSCs were differentiated before culturing with aneurysmal 
tissue, the differentiated MSCs increased the gene expression of elastin and elastin 
deposition79,80.  Both of the studies suggest MSCs and differentiated MSCs have the ability 
to stimulate the regeneration of elastin when cultured with aneurysmal tissue.  It is crucial 
now to determine if MSCs can produce the same results in vivo and develop a means to 
deliver the MSCs to the AAA.    
2.4.2. Elastin regeneration using pharmaceuticals 
 
 There are currently no FDA-approved or proven drugs for AAA treatment and 
almost none capable of regenerating elastic matrix.  Drugs in the development pipeline for 
small AAA management including statins5,67,81, tetracyclines21,60,69, and ACE inhibitors82 
only seek to attenuate chronically overexpressed proteases in the AAA wall.  This can at 
best lead to slowed AAA growth.  There is no impetus to regenerative repair of disrupted 
elastic matrix structures.  There is therefore, a compelling need for non-surgical, drug based 
therapy targeting and reversal of pathophysiologic changes in the AAA wall which include 
chronic proteolysis and lack of autoregenerative repair of the elastic matrix.   
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The inhibition of MMP activity is an area of focus for treating AAAs so there have 
been great strides in producing synthetic MMP inhibitors such as batimastat, doxycycline 
and other tetracycline derivatives69.  Synthetic MMP inhibitors reduced aneurysm dilation 
in several rat models by controlling the inflammatory response83,84.  The MMP inhibitors 
produced promising results but also caused adverse musculoskeletal side effects likely 
related to their systemic biodistribution and high dosing levels85,86.  Recently, tetracycline 
based drugs have been shown to inhibit MMP activity87.  One of the most studied is the 
drug, doxycycline (DOX), which has been shown in several animal models of AAAs to 
slow AAA development87.  When DOX was administered subcutaneously in a rat elastase 
injury AAA model, there was a significant decrease in AAA growth while oral dosing 
showed a 50% reduction in AAA growth rate in Ang II mice88.  DOX has also shown 
promise in clinical trials in slowing AAA growth upon oral therapy89,90.  This was primarily 
attributed to decrease in elastolytic MMPs 2 and 9 in the AAA wall.  Despite this promise, 
the clinical outcomes are inconsistent largely due to difficulties in delivering a defined 
steady dose of the drug in the AAA wall, sustaining its effect in the long term, and rapid 
drug inactivation associated with oral dosing.  In addition, the high oral DOX doses (30-
50 mg/kg/day) necessary to ensure sufficient levels of MMP inhibition in AAA tissue 
causes body wide side effects (e.g., musculoskeletal pain, inflammation, tendonitis) and 
also further inhibits the already poor elastin regeneration and crosslinking in the AAA 
wall85.   This negates prospects to restore elastin homeostasis in the AAA wall, a key 
requirement for arresting or reversing AAA growth. 
In recent studies in our laboratory, we have shown that at much lower doses (< 5 
µg/ml) than that achieved in the AAA wall with oral dosing (50 mg/kg/day equivalent to 
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~50 µg/ml), DOX maintains its anti-MMP effects but also has significant pro-elastogenic 
effects as well, which was a novel finding (Unpublished Data).  To achieve this benefit, 
modalities to ensure targeted, predictable, sustained and steady low level DOX dosing 
locally in the AAA wall are necessary.  Nanoparticles (NPs) offer several advantages for 
this purpose.  
2.5. Nanoparticles for drug delivery 
 
Nanoparticles provide unique opportunities as a treatment option that are not 
available in pharmaceutical and cell-based therapies.   Limitations of pharmaceuticals 
include short half-lives, poor bioavailability, or physical and chemical instability91.  These 
limitations have led researchers to study nanoparticles in which many of the poor 
characteristics from pharmaceuticals can be overcome and a unique environment for drug 
delivery can be designed25.  One of the largest obstacles to overcome in using stem cells as 
a therapy is their delivery to the treatment site as well as the processing and purifying of 
the cells along with tracking the cells in vivo.  Upon implantation in the body, stem cells 
have the ability to form tumors if not properly controlled or delivered to the target area.  
This gives nanoparticles (NPs) a distinct advantage as a therapy option.  However, to be an 
effective drug delivery system, the NP needs to consist of three components: the core 
material, the ability to carry therapeutics, and surface modifiers92.   
2.5.1. NP characteristics 
 
 An important feature of NPs is their composition or core material92.  Most NPs are 
formulated using either synthetic or natural polymers however other nanoparticles have 
been generated using lipids to create liposomes or silica and alumina to create inorganic 
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nanoparticles25.  In liposomes, the hydrophilic head and hydrophobic tail of the lipid 
aggregate to form an aqueous core in which therapeutics can be encapsulated92.  The use 
of liposomes to deliver therapeutics is currently the most developed system with the largest 
number of clinical trials and treatments in the marketplace.  However, this may be due to 
the relatively new focus on polymeric materials compared to liposomes92.  Synthetic 
polymers have advantages over natural polymers in terms of drug delivery and release 
kinetics, but the formulation conditions of synthetic polymers limits their use.  Some 
common synthetic polymers used are biodegradable polymers such as poly (D, L-lactide-
co-glycolide) (PLGA) and polylactide (PLA).   
Both PLGA and PLA polymers are approved by the US Food and Drug 
Administration for safe human use and are commercially available in various molecular 
weights and co-polymer compositions25,93.  PLGA is one of the most commonly used 
polymers due to the degradation products being lactic acid and glycolic acid which are 
easily metabolized in the body through the Krebs cycle thereby limiting the toxicity of the 
NPs93,94.  The biodegradable polymers can be formulated to encapsulate drugs, proteins or 
DNA and act as a delivery system.  The polymer matrix helps prevent degradation of the 
encapsulated drug and allows for control over drug release.  Drug release is altered by 
changing the ratio of drug to polymer or changing the polymer molecular weight and 
composition95.  
Nanoparticles are submicron-sized polymer particles and have characteristics 
different than bulk materials24,96.  Nanoparticles have advantages over larger sized particles 
when targeting cells for treatment.  Studies comparing uptake of particles with different 
sizes have shown the smaller particles are more readily taken up by cells.  The uptake of 
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100 nm particles was 15 to 250 fold greater than particles of 1 and 10 µm with respect to a 
rat intestinal model.  It was also found particles in the nanometer range could pass through 
the submucosal layer while larger particles were trapped in the epithelial lining28.  The 
uptake of the NPs into the cell are mediated through a concentration and time-dependent 
endocytosis process.  Once the NPs are taken up by the cell, and depending on their surface 
charge, undergo a surface charge change from anionic to cationic in the endo-lysosomes 
disrupting the membrane.  The NPs do not remain in the endo-lysosomes for long because 
of this and they quickly enter the cytoplasm following uptake95.  The surface characteristics 
of the NPs play a vital role in their escape from the endo-lysosomes which effects their 
retention within the cell.  The surface characteristics that influence NP retention in the 
cytosol include zeta potential and hydrophilicity95. 
2.5.2. Tissue targeting of NPs 
 
While the use of nanoparticles as drug delivery systems has been around for 
decades, extensive research has recently been conducted on utilizing nanoparticles as a 
targeted delivery system24.  Nanoparticle surfaces have been modified to effect the 
characteristics, uptake, and localization of the nanoparticles within the body with much 
research conducted to identify surface modifications to increase nanoparticle targeting to 
specific tissues.  Nanoparticles have been altered with several types of surface 
modifications such as polysorbate 80, PEG, and DMAB  to change nanoparticle behavior 
in the body23,26.  Studies have shown the polysorbate 80 modification can help move drug-
loaded nanoparticles through the blood-brain barrier while the addition of heparin or 
DMAB can increase nanoparticle retention in arteries26.  Previously published research 
from our group, indicates modifying the surface with DMAB increases the nanoparticle 
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binding to elastin23.  Each surface modification imparts a unique characteristic on the NP 
so it’s critical to understand how to utilize these qualities.  Utilizing these qualities of 
surface modification, targeting of nanoparticles to specific regions of the body is an area 
of great promise and continued interest.   
Targeting of NPs to specific tissues/regions is an area of interest in treating 
diseases.  Extensive research has been conducted on treating cancer using NPs loaded with 
chemotherapeutic drugs.  In order to target cancer cells, chemotherapy drugs are 
administered at high concentrations which has adverse side effects on the entire body but 
with NPs the systemic concentration could be significantly decreased and thereby reduce 
side effects.  For example, paclitaxel loaded NPs were modified with transferrin to increase 
cellular uptake.  After a week of treatment in vitro, the modified NPs demonstrated an 80% 
decrease in cell growth compared to a 40% decrease with unmodified NPs.  The largest 
change was in comparison to the paclitaxel solution where there was a 20% decrease in 
growth95.  This demonstrates the effectiveness of using NPs as delivery systems.    
In order to increase the targeting capabilities of NPs, understanding the biology of 
the target tissues is crucial.  Movement of nanoparticles into the intracellular space is 
accomplished through endocytosis which can be separated into three subtypes: 
phagocytosis, pinocytosis and receptor mediated endocytosis.   Phagocytosis occurs in 
select cell types such as macrophages and neutrophils where particles up to 10 µm are 
ingested.  However, in pinocytosis submicron particles can be ingested by nearly all cell 
types leading to greater access of nanoparticles to cells25.  This difference in uptake 
depends on nanoparticle size and can be used to differentiate which cells ingest 
nanoparticles.  Expression of receptors that can be targeted can change depending on tissue 
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type and disease state so identifying these changes allows for the determination of specific 
targets25,28.  Finally, modifying the surface of the NP with a primary antibody has been 
linked to increased targeting capabilities (Figure 2.9).  The functionalization of the NP 
surface with an antibody can be accomplished through adsorption of a compound to the 
surface or though covalently linking the compound to the polymer95.  In this method, the 
active site of the antibody is left free to bind to target compounds.  If the target is a receptor 
on the cell surface, this can effectively increase the localization of the NP to the tissue.   
 
Figure 2.9. Functionalization of nanoparticles using a primary antibody surface 
modification.   
 
Another option being actively explored to increase localization of NPs to specific 
tissues utilizes the loading of iron oxide into NPs to generate superparamagnetic iron oxide 
NPs (SPIONs).  Currently, there are imaging contrast agents commercially available 
utilizing SPIONs to improve imaging of the liver and GI tract.  Recently, SPIONs have 
been combined with therapeutics to investigate improvement in treatments with the use of 
magnetic fields97–99.  The combination of imaging agents and therapeutics is described in 
more detail in the following sections.    Iron oxide particles alone are hydrophobic leading 
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to aggregation resulting in large clusters.  The formation of these large clusters is 
undesirable so modifying the surface or encapsulating the iron oxide particles in polymer 
scaffolds reduces this effect and increases their effectiveness as a treatment option100.  The 
use of SPIONs originally focused on delivery of peptides, DNA molecules and 
chemotherapeutic drugs but the focus has shifted to using SPIONs to fight infections, as 
anti-inflammatory reagents, or dissolve blood clots99.  Several studies have confirmed the 
capabilities of SPIONs to target tumors with concentration increases from 4 to 200 times 
greater.  Using an implanted permanent magnet, cytotoxic SPIONs were successfully 
localized to solid tumors in hamsters.  The localization to the tumor increased the anti-
tumor activity as well as eliminated unwanted side effects such as weight loss99.  Despite 
the attractive NP targeting possibilities with SPION incorporation, there are regulatory 
challenges due to the designation of SPION-loaded/modified polymer NPs as combinatory 
devices and questions regarding long-term safety and biodistribution of the SPIONs, which 
need to be elucidated.  Therefore, alternative safer and less complex targeting modalities 
(e.g., antibody or peptide mediated targeting) must be explored.  
2.5.3. Environmental activation of NPs 
 
 While surface modifications improve targeting, activation of nanoparticles as drug 
delivery systems has become an area of interest as it helps create specificity in drug release.  
Activation of these nanoparticles can occur through two main modes – exogenous and 
endogenous activation101,102.  In exogenous activation, the NPs are stimulated through an 
external stimuli to control drug release.  This can be accomplished through magnetic fields, 
light, or radio frequencies91,101,103.  Using an external stimulus provides greater control of 
drug release allowing for high concentrations of therapeutics to be delivered in specific 
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sites while limiting systemic concentrations.  Also, the use of magnetic fields to stimulate 
drug release can serve a dual purpose as it can help localize NPs to the treatment area as 
well as control drug release.  Using magnetic guidance for SPIONs has shown potential in 
experimental cancer treatments through an increase in drug concentration in solid 
tumors102.  Beyond the localization of nanoparticles, the magnetic field has shown to trigger 
the drug release in certain materials.  In a ferrogel composed of micelles encapsulating 
SPIONs and a hydrophobic drug, the applied magnetic field causes the micelles to be 
squeezed through SPION interactions thereby releasing the drug102.  The use of SPIONs 
and the MRI may play a vital role in treating AAAs as the treatment and imaging could be 
performed at the same time.  Passive monitoring of the AAA is currently performed and 
the addition of the SPIONs could provide a treatment option without significantly changing 
current treatments.   
The endogenous activation relies on a variety of differences between healthy and 
diseased tissue to cause drug release from NPs.  Factors that influence the activation of 
NPs include pH, enzyme concentrations, and hypoxia91,101,103.  Using pH sensitive NPs 
allows for targeting and triggered release of drugs in specific organs as well as specific 
intracellular compartments.  pH sensitive NPs utilize two main strategies for triggered 
release including polymers that undergo conformational or solubility changes when the pH 
changes as well as systems where the bonds in the polymers are broken when the pH 
changes102.  Another possible endogenous activation system relies on enzymatic activity.  
In pathological conditions, the expression of enzymes may be altered and can be a target 
for NPs.  Studies have reported the use of peptide sequences susceptible to MMPs as linkers 
in nanoparticles.  As MMPs cleave the peptides, the encapsulated drugs are released 
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thereby limiting their release to areas of high MMP concentration102.  The use of enzyme 
concentrations to control drug release could provide valuable treatment options within 
AAAs as several proteins have been identified to be over expressed in the diseased tissue.  
2.5.4. NP treatments and diagnostics 
 
 Treatments using nanoparticles have been approved for human use by the FDA to 
treat disorders ranging from cancer to infection but the number of options is relatively 
small25,104.  However, there are a large number of clinical trials underway which could lead 
to a dramatic increase in nanoparticle treatments.  One study published in 2013 evaluated 
the developments of nanoparticles and their use in clinical trials and found nearly 800 
potentially relevant clinical trial results.  Of these 800 clinical trials, 141 were unique 
products with approximately 40 already approved for use104.  This number is expected to 
grow as interest in nanoparticles and nanomaterials increases.   
 Imaging is a large portion of diagnosing and the first step to treat many disorders.  
In medical imaging, there are two approaches: anatomic imaging to identify structural 
information and molecular/functional imaging to provide physiological and cellular 
information.  Anatomical imaging does not always require contrast agents but for 
molecular imaging the contrast agents are essential.  Imaging contrast agents include small 
molecules, proteins, and nanoparticles105.  While most scans use small molecules as 
contrast agents, interest in nanoparticles has grown and led to new applications.  These 
include intense and long lasting imaging signals, the ability to have different targeting 
strategies, theranostic capabilities, and detection by several imaging instruments.  One of 
the most intriguing possibilities is the use of nanoparticles as theranostics in which the 
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imaging agent can also deliver therapeutics.  The use of nanoparticles as theranostics has 
been studied with doxorubicin loaded ferumoxytol nanoparticles to treat cancer.  The 
nanoparticles, or SPIONs, generate a signal when using MRI but may also be able to treat 
cancer by releasing the encapsulated doxorubicin105.  More studies are confirming the 
increased localization of SPIONs to tumors using MRI which may eventually lead to 
improved drug delivery106,107.  
 Apart from imaging agents, the use of nanoparticles has been extensively 
researched in the treatment of cancer.  The most common treatment of cancer involves 
using one or more cytotoxic small molecules to kill cancer cells.  Unfortunately, these small 
molecules do not recognize cancer cells specifically and will kill other cells types leading 
to many unwanted side effects108.  To limit side effects, targeted therapy has been explored 
to reduce exposure to cytotoxic small molecules.  Two modes of targeted therapy using 
nanoparticles have been explored including direct and indirect treatment methods.  Indirect 
treatment relies on an immune response that causes cancer cell apoptosis or inhibits 
angiogenesis108.  Nanoparticles loaded with cancer treating drugs have shown much 
promise.  However, different drugs have different mechanisms of action and require 
delivery to specific target areas.  Paclitaxel affects microtubules so it needs to localize in 
the cytoplasm where other drugs need to migrate into the nucleus to be effective108.  In 
treating AAAs, the direct treatment method will provide the necessary cellular response to 
stimulate elastin regeneration.   
 Nanoparticles have been used as detection agents and treatment options for several 
vascular diseases including atherosclerosis and thrombosis109.  As previously mentioned, 
the vascular wall is a complex and difficult tissue to treat and regenerate.  The vascular 
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wall cannot be treated like many other tissues because of the large amount of blood flow.  
Administering a therapeutic drug directly does not induce therapeutic benefits due to rapid 
drug removal from the site as well as the short half-life of drugs in plasma.  Also, 
conventional therapies for treating disorders in the vascular wall do not produce the desired 
results because many therapeutic agents are toxic at the dose required to be therapeutic as 
well as having systemic side effects109.  This has led to much research into using 
nanoparticles as targeted drug delivery systems.   
Using targeted drug delivery systems allows for low systemic concentration but 
high concentration in areas of interest as well as a sustained and controlled release that can 
be extended over a long period of time.  The success of nanoparticles targeted to the 
vascular wall are affected by the size of the particle, the blood flow type, and the vascular 
wall shear rate.  In this study, we aim to utilize targeted drug-loaded nanoparticles, with a 
sustained and controlled drug release, to stimulate regeneration of the disrupted elastic 
matrix associated with abdominal aortic aneurysms and investigate the efficacy of antibody 
based targeting on these NPs to the AAA wall with no adverse impact on their physical 
and functional properties, which are vital to effective regenerative repair of the AAA wall 
ECM.   
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CHAPTER III 
MATERIALS AND METHODS 
 
3.1. Induction of AAA in rat model via elastase infusion 
 
 All rat surgeries were performed with IACUC approval at the Cleveland 
Clinic (2016-1581).  Acepromazine (0.5 mg/kg) was administered subcutaneously 
approximately 30 minutes before anesthesia induction.  Elastase solution was prepared (20 
Units/ml, Sigma) and stored on ice until use.  Immediately prior to anesthesia induction, 
buprenorphine hydrochloride (0.03 mg/kg) was administered subcutaneously.  The rat was 
moved to the anesthesia induction chamber (oxygen flow rate 1 L/min, 2.5% isoflurane) 
for 7-8 minutes until anesthetized.   
Once anesthetized, ophthalmic eye ointment was applied to both eyes and the rat 
was placed on the surgery table and its nose inserted into the nose cone.  The isoflurane 
concentration was reduced to 2% for the duration of the procedure.  The hair from the 
abdomen was clipped, the abdominal skin sterilized using betadine and alcohol scrubs with 
application proceeding from the inside out.  Immediately before the surgical procedure, 
0.25% Bupivacaine (2-8 mg/kg; analgesic) was administered subcutaneously at the 
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incision site.  The abdominal cavity was exposed by a laparotomy and the abdominal wall 
was held open using retractors.  The exposed intestines and other internal organs (stomach, 
pancreas, liver, etc.) were removed to outside the body cavity and were covered with 
moistened sterile gauze to prevent drying during the procedure.  Using fine forceps, the 
aorta was exposed by removing surrounding fat and connective tissue.  Once the aorta was 
exposed, images were taken using a microscope to allow for diameter determination.  The 
blood flow in the aorta was stopped by using a plastic clamp at the proximal and distal ends 
of the abdominal aorta.  Care was taken to ensure the aorta was completely sealed before 
infusion.  A micro cannula system (Braintree Scientific, Inc.) was inserted into the aorta 
without passing completely through.  The elastase solution was infused through the micro 
cannula system into the aorta and held for 20 minutes.  The solution was removed from the 
aorta and the cannula system removed.  The aorta was either sutured or glued shut using a 
fibrin glue (Tisseel Fibrin Sealant; Baxter; Westlake Village, CA).  Images of the aorta 
were taken post treatment.  The intestines were replaced and the abdomen sutured with the 
muscle layer sutured using 4-0 vicryl non-absorbable nylon stiches in a running pattern and 
the skin sutured using 4-0 silk stiches in an interrupted pattern.  During suturing, the 
isoflurane was reduced to 1.5% to begin recovery.   
The animal was removed from isoflurane and placed on a heating pad (37 °C) to 
continue recovery before being moved to its cage and placed on a towel to finish 
recovering.  While in the cage, food and a water-gel pack was placed on the cage floor to 
allow access during recovery.  Once the animal has recovered enough to move around the 
cage, the cage was returned to the BRU.  Pain from the surgery is managed through twice 
daily injections of buprenorphine hydrochloride (0.03 mg/kg) for 72 hours.  
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3.2. Isolation and culture of SMCs from elastase perfusion-induced rat AAAs 
 
 EaRASMCs were harvested from multiple (n = 3) adult male Sprague-Dawley rats 
at 14 days following elastase infusion, as we have previously published110. The AAA 
segments were isolated following laparotomy and the intimal layer scraped off. The medial 
layer was then separated from the adventitia, dissected into ~0.5 mm long slices, and rinsed 
in sterile phosphate-buffered saline (PBS). The tissue was digested in DMEM-F12 medium 
(Invitrogen, Carlsbad, CA) containing 125 U/mg collagenase (Worthington Biochemicals; 
Lakewood, NJ) and 3 U/mg elastase (Worthington Biochemicals) for 30 min at 37 oC, 
centrifuged (400g, 5 min) and cultured in T-75 flasks in DMEM-F12 medium containing 
10% v/v of fetal bovine serum (FBS; PAA Laboratories; Etobicoke, Ontario) and 1 % v/v 
of penicillin-streptomycin (PenStrep; Thermo Fisher; South Logan, UT). At 70% 
confluence, the primary EaRASMCs from individual rats (n = 3) were pooled and 
passaged. 
 Primary rat aortic SMCs (RASMCs; healthy cell controls) were isolated from aortae 
of multiple (n = 3) healthy Sprague-Dawley rats, in a similar manner as previously 
described for EaRASMCs, pooled, passaged, and used in culture experiments at passage 
<6.   
3.3. Experimental design for cell culture 
 
 In order to study the effect of cathepsin K antibody-conjugated DOX-NPs and 
unconjugated NPs on cellular elastic matrix synthesis, EaRASMCs were seeded at 30,000 
cells per well in wells of a 6-well plate, and cultured for 21 days in DMEM-F12 medium 
supplemented with 10% v/v fetal bovine serum (FBS) (Invitrogen), 1% v/v PenStrep (CCF 
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Cell Services), and 50 ng/ml of tumor necrosis factor-α (TNF-α) (Thermo Fisher; Waltham, 
MA). The media from each well was removed and centrifuged (5 min, 12,000 RPM) to 
pellet the NPs.  The NPs were re-suspended in fresh medium before being added back into 
each well.  Culture groups included untreated EaRASMC cultures (treatment control), 
EaRASMCs cultured with unconjugated NPs loaded with 2% w/w of doxycycline hyclate 
(DOX; Sigma Aldrich), and cathepsin K Ab-conjugated NPs loaded with 2% w/w of DOX. 
In the latter cases, the NPs were added on Day 1 following an overnight incubation at a 
concentration of 0.2 mg/ml.  
 To study the migration of Ab-modified NPs through the endothelial cell layer, 
human umbilical vein endothelial cells (HUVECs) were cultured in vascular cell basal 
media (ATCC; Manassas, VA) supplemented with Endothelial Cell Growth KIT-VEGF 
(ATCC; Table 3.1).  The HUVECs were seeded at 30,000 cells per well or per collagen-
coated PET membrane (Millipore; Billerica, MA) and cultured with the medium 
supplemented with vascular endothelial growth factor (VEGF; 5 ng/ml; ATCC).  The cells 
were stimulated with 10 ng/ml of TNF-α for subsequent experiments (immunofluorescent 
labeling and treatment with NPs and Ab-modified NPs).  The cells were cultured with the 
NPs at a concentration of 0.2 mg/ml.   
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Table 3.1. Endothelial Cell Growth Kit-VEGF added to 500 ml of vascular basal media 
for the culturing of HUVECs. 
Component Volume Final Concentration 
rh VEGF 0.5 ml 5 ng/ml 
rh EGF 0.5 ml 5 ng/ml 
rh FGF basic 0.5 ml 5 ng/ml 
IGF-1 0.5 ml 15 ng/ml 
L-glutamine 25.0 ml 10 mM 
Heparin sulfate 0.5 ml 0.75 Units/ml 
Hydrocortisone hemisuccinate 0.5 ml 1 µg/ml 
Fetal Bovine Serum 10.0 ml 2% 
Ascorbic Acid 0.5 ml 50 µg/ml 
 
3.4. Formulation of fluorescein-loaded, Alexa Fluor 633-loaded, VivoTag® 800-
loaded, DOX-loaded, and blank PLGA NPs 
 
 Poly (DL-lactic-co-glycolic acid) (PLGA; 50:50 lactide: glycolide; Durect 
Corporation; Birmingham, AL) NPs loaded with fluorescein (Chemicon; Temecula, CA), 
Alexa Fluor 633 (AF633) (Invitrogen; Carlsbad, CA), or VivoTag® 800 (PerkinElmer; 
Waltham, MA) were prepared using a double emulsion solvent evaporation technique. 
PLGA (50 mg) was dissolved in 2 ml of chloroform (Fisher Scientific, Fair Lawn, NJ) and 
0.1 ml of a 1 mg/ml solution of fluorescein, AF633, or VivoTag® 800 was added.  The 
mixture was emulsified on ice using a probe sonicator (Q500; QSonica LLC; Newtown, 
CT) for 30 seconds at an amplitude of 20% to form a water-oil emulsion.  Similar to loading 
of the fluorescent dye, the DOX-loaded NPs were prepared using an aqueous DOX solution 
containing a 2% w/w ratio of DOX: PLGA and emulsified into the PLGA solution using a 
probe sonicator.  For all of the  NP formulations, 6 ml of an aqueous phase consisting of 
nanopure water and surfactant, didodecyldimethylammonium bromide (DMAB; Sigma-
Aldrich, St. Louis, MO), was added and sonicated again for 60 seconds (30 seconds on – 
10 seconds off - 30 seconds on) on ice at 20% amplitude to form the water-in oil-in water 
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double emulsion. The double emulsion was stirred for 16 hours at room temperature and 
desiccated for 1 hour under vacuum. The samples were separated by ultracentrifugation 
(35,000 rpm, 30 minutes; Beckman L-80, Beckman Instruments, Inc., Palo Alto, CA), the 
supernatant removed and the NPs washed with nanopure water to remove residual DMAB 
and unencapsulated loading compounds, sonicated to re-suspend the NPs, and a repeat 
ultracentrifugation (30,000 rpm, 30 minutes).  Following the second ultracentrifugation 
step, the NPs were re-suspended in 6 ml of nanopure water and sonicated before aliquoting 
into cryovials.  The cryovials were immersed in liquid nitrogen, to flash freeze the NPs, 
and stored at -80°C overnight.  The NPs were lyophilized for 48 hours to obtain a dry 
powder. Samples were kept covered throughout this procedure to ensure the fluorescent 
dye did not undergo bleaching.  Following the methods as previously described, blank 
PLGA NPs were formulated using DMAB as the surfactant.   
3.5. Determination of NP size and surface zeta potential 
 
  Mean hydrodynamic diameters of the NPs were determined using a dynamic light 
scattering technique, and their mean zeta potentials (surface charge) were determined via 
a phase analysis light scattering technique using a commercial particle-sizing system 
(PSS/NICOMP 380/ZLS, Particle Sizing Systems; Santa Barbara, CA).   
 To determine the particle size, a small aliquot of the NPs (~ 5 µl) was diluted in 
nanopure water and placed in a small glass vial.  The glass vial was wiped clean to ensure 
no interference.  The glass vial was inserted into the particle-sizing system and the particle 
size was measured over a 2 minute cycle.  The results were displayed as a Gaussian 
distribution.  To determine the zeta potential, the NPs (~0.5 ml) was added to ~2.5 ml of 
nanopure water and transferred to the cuvette.  The electrode was rinsed with deionized 
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water and placed on the cuvette.  The cuvette and electrode were placed into the instrument 
and the electrode connected.  Once the electrode is connected the zeta potential was 
measured over a 5 minute cycle.   
3.6. Preparation of cathepsin K Ab-modified NPs 
 
3.6.1. Adsorption of cathepsin K Ab to NP surface  
 
 Fluorescent dye loaded-NPs (AF633) were suspended in PBS (pH 7.4, 0.5 mg/ml) 
and a 490 µl aliquot of this was mixed with 10 µl of cathepsin K Ab (200 µg/ml; rabbit 
anti-rat; Santa Cruz Biotechnology, Inc.; Dallas, TX).  A mixture containing 490 µl of the 
NP dispersion and 10 µl PBS was used as a control.  These mixtures were stirred (2, 5, or 
24 hours) and centrifuged (12,000g, 10 min) to separate the free antibody from NPs.  The 
pellet containing cathepsin K Ab-adsorbed NPs were washed twice with PBS and re-
suspended in 500 µl of PBS (pH 7.4). 
3.6.2. Covalent conjugation of cathepsin K Ab to NP surface  
 
1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide HCl (EDC; Thermo Fisher; 
Rockford, IL), a cross-linking reagent, was used to generate a covalent bond between free 
carboxylic acids on the PLGA NP surface and the primary amine group on the cathepsin 
K Ab. The NPs were suspended in 2-(N-Morpholino)ethanesulfonic acid (pH 5.5, MES; 
Sigma-Aldrich) at a concentration of 0.5 mg/ml and 490 µl of this mixture was mixed with 
10 µl of cathepsin K Ab followed by the addition of 100 ng of EDC .  Two controls were 
run including one without EDC and one without EDC and antibody.  The mixtures were 
stirred at 24C for 5 hours followed by centrifugation (10 min, 12,000 rpm) and the 
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supernatant discarded and the NP pellet washed two times with PBS (pH 7.4).  The NPs 
were finally re-suspended into PBS to the desired concentrations.   
3.7. Assessment of cathepsin K Ab incorporation on NP surface 
 
3.7.1. Fluorescence spectroscopy to assess cathepsin K Ab binding to NPs 
 
 A fluorescein-tagged goat anti-rabbit secondary antibody (Chemicon, Temecula, 
CA), was used to qualitatively determine the relative binding of the cathepsin K Ab on the 
surface of the NPs.  Cathepsin K Ab-modified NPs were treated with the secondary 
antibody (4 oC, 1 h, 1:500 dilution).  The samples were centrifuged (12,000g, 10 min) and 
the pellets washed twice with PBS, to remove any unbound secondary antibody, and then 
re-suspended in 500 µl of PBS.  Three 150 µl aliquots per sample were placed in the wells 
of a 96-well microplate.  The fluorescence intensity due to fluorescein was measured (λex 
= 493 nm and λem = 525 nm) using a SpectraMax M2e microplate reader (Molecular 
Devices, Sunnyvale, CA) as well as visual confirmation using a fluorescent microscope.   
3.7.2. Measurement of cathepsin K Ab conjugation efficiency 
 
 The cathepsin K Ab was covalently conjugated to AF633-loaded NPs over 5 hours 
as described previously, with proper controls. Following conjugation and washing, an 
Alexa Fluor (AF) 546-conjugated donkey anti-rabbit (1:1000 dilution; Thermo Fisher 
Scientific) was used to fluorescently tag the NP-bound cathepsin K Ab (25 C, 1 hour).  
Samples were centrifuged (12,000g, 10 min), washed twice with PBS, and re-suspended in 
PBS at a concentration of 0.5 mg/ml.  Three 150 µl aliquots of each sample was added to 
a 96-well microplate and the fluorescence of fluorescein (λex = 493 nm and λem = 525 nm) 
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and Alexa Fluor 546 (λex = 556 nm and λem = 573 nm) were measured using a microplate 
reader. The NPs were aliquoted onto glass cover slips, mounted, and visualized on a 
microscope (Leica TCS SP5 II, Leica Microsystems, Inc., Buffalo Grove, IL) to detect 
cathepsin K Ab-conjugated NPs exhibiting both green (fluorescein) and red (AF 546) 
fluorescence. 
3.7.3. Assessing retention of conjugated and absorbed cathepsin K Ab on NP surface 
 
 To determine whether chemical conjugation or physical adsorption resulted in 
stable binding of cathepsin K Ab to the NP surface, Alexa Fluor 633 (Invitrogen) was 
loaded into the NPs as previously described.  Cathepsin K Ab modification of the NPs was 
performed as described above for both methods (Sections 3.6.1 and 3.6.2).  An Alexa Fluor 
488-conjugated goat anti-rabbit secondary antibody (1:1000 dilution; Invitrogen) was used 
to fluorescently tag the cathepsin K Ab.  The NPs were centrifuged (12,000g, 10 min), 
washed twice with PBS, re-suspended in PBS (0.5 mg/ml) and a fluorescent microscope 
used to visualize the NPs exhibiting both red (AF633) and green (AF488) fluorescence. 
 To determine fluorescence intensity due to NP surface-bound cathepsin K Abs, a 
corrected total fluorescence (CTF) protocol was used.  Briefly, individual NPs were 
selected using the drawing tool in ImageJ software® to obtain an integrated density for both 
red and green fluorescence.  The integrated density was used to calculate the corrected total 
fluorescence at Day 1 and Day 14.  The CTF is calculated by: (Integrated Density – (Mean 
Fluorescence of Background * Area of Selected NP)).  To determine the ratio of FITC 
bound to the NP surface, the CTF of FITC (adsorption n = 132, n = 130 and conjugation n 
= 154, n = 207) was divided by the average CTF of AF633 for each test case.   
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3.8. Verifying cathepsin K overexpression by aneurysmal cells and their targeting 
by NPs 
 
3.8.1. Assessing cathepsin K expression by EaRASMCs in culture 
 
EaRASMCs (passage 3) and RASMCs (healthy cell controls) were seeded at 
30,000 cells/well, and cultured for 2 weeks in six-well plates in DMEM-F12 medium 
containing 10% v/v FBS and 1% v/v PenStrep.  Half of the EaRASMC cultures received 
medium supplemented with 50 ng/ml of TNF-α in order to simulate the inflammatory 
aneurysmal tissue environment.   
For immunofluorescence visualization of cathepsin K expression, after a further 24 
hours of culture, all cell layers were fixed in 4% v/v paraformaldehyde, permeabilized with 
Triton-100 (VWR International; UK) and labeled with the primary cathepsin K Ab (1:100 
dilution) and a secondary AF 546-tagged secondary antibody (1:1000 dilution). DAPI 
(Vector Labs; Burlingame, CA) and AF488-Phalloidin (Molecular Probes; Temecula, CA) 
were used to stain the nuclei and actin cytoskeleton, respectively. The cell layers were 
imaged on a fluorescent and confocal microscope. 
3.8.2. Assessing cathepsin K expression in matrix-injured arteries 
 
Cathepsin K expression in elastase injured arteries (Lampire Biological 
Laboratories, Pipersville, PA) was compared to expression of the housekeeping protein, β-
actin, using western blot.  Porcine carotid arteries (n = 3) were infused with either elastase 
(20 units/ml, Sigma) or 0.9% v/v sterile saline.  The end of each artery was clamped shut 
and a catheter was used to infuse 1 ml of solution into the lumen.  The other end of the 
artery was clamped shut and the arteries were incubated at 37 °C for 20 minutes.  After 
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incubation, the samples were washed with PBS to remove any residual elastase or saline.  
The arteries were then cut into segments of similar length (~15 mm) and flash frozen in 
liquid nitrogen.  After storage overnight (-80 °C), the tissue segments were lyophilized to 
produce a dry sample.  The dry weight of each segment was obtained.  The dry arteries 
were placed in RIPA buffer (Thermo Scientific) containing 1% HaltTM protease inhibitor 
(Thermo Scientific), homogenized and vortexed for one hour.  The samples were 
centrifuged (10,000 rpm, 10 minutes) to pellet the cell debris and the supernatant removed 
and stored at -80oC.  The samples were thawed and prepared for western blot (Table 3.2) 
followed by heating for 10 minutes (70°C).   
Table 3.2. Preparation of samples for western blot.  The amounts listed are for one sample 
to be loaded into one well of the western blot gel.  
  
Reagent Volume (µl) 
Sample in RIPA Buffer 15.6 
Reducing Agent 2.4 
Sample Buffer 6.0 
 
A 22.5 µl aliquot of each sample was loaded under reduced conditions into each 
lane of a 4-12% sodium dodecyl sulfate polyacrylamide gel electrophoresis gel (SDS-
PAGE), along with a SeeBlue pre-stained molecular weight ladder (Invitrogen).  The gels 
were transferred onto nitrocellulose membranes (Invitrogen).  Subsequently, the 
membranes were blocked for 1 hour with Odyssey Blocking Buffer (LI-COR Biosciences; 
Lincoln, NE; 1:1 dilution Blocking Buffer: PBS).  After blocking, the membranes were 
labeled (16 hour, 4C) with a rabbit cathepsin K Ab (1:200 dilution) and a mouse 
monoclonal antibody against β-actin (1:1000; Sigma Aldrich).  Following the primary 
antibody incubation, the membranes were washed with PBST (PBS+0.1% v/v Tween, 10 
min, 10 min, 5 min).  Secondary antibody labeling occurred at room temperature for 1 hour  
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on a shaker using IRDye® 680LT goat-anti-rabbit (1:15,000 dilution; LI-COR Biosciences) 
and IRDye® 800CW (1:20,000; LI-COR Biosciences).  The membranes were protected 
from light to prevent photo-bleaching.  The secondary antibody was removed by washing 
the membrane with PBST (10 min, 10 min, 5 min) and the membrane was then stored in 
PBST (4 °C).  A LI-COR Odyssey scanning system was used to detect the protein bands.  
The intensities of the cathepsin K bands were quantified using Image Studio® and 
normalized to their respective β-actin bands to allow reliable comparison between different 
samples in the same blot. 
3.8.3. NP targeting of cathepsin K in in vitro EaRASMC cultures 
 
 Using the covalent conjugation method, AF633-loaded PLGA NPs were 
conjugated with cathepsin K Ab.  RASMCs and EaRASMCs (passage 3) were seeded at 
75,000 cells per well and cultured for 13 days in six-well plates. The EaRASMCs were 
cultured in DMEM-F12 supplemented with 10% v/v FBS and 1% v/v PenStrep 
supplemented with 50 ng/ml of TNF-α.  Following 24 hours of incubation, the cell cultures 
received the cathepsin K Ab-conjugated AF633-encapsulated NPs. The final concentration 
of NPs was 0.5 mg/ml. After a further 24 hours, the cell layers were fixed, stained with 
AF488-Phalloidin (green for cytoskeleton; Molecular Probes) and mounted on slides with 
VectaShield containing DAPI (blue for nuclei; Vector Labs, Burlingame, CA). 
3.8.4 Assessing elastase-mediated disruption of the porcine carotid artery wall 
 
 Porcine carotid arteries were thawed, washed with PBS, and the length of each 
artery measured.  One end of the artery was clamped shut and a catheter used to infuse 1 
ml of solution (elastase; 20 units/ml; Sigma or 0.9% v/v sterile saline) before the other end 
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was clamped shut.  With the arteries clamped, the artery segments were incubated for 20 
minutes at 37°C.  Following incubation, the arteries were washed with PBS to remove any 
remaining infusion solution before continuing with additional experiments.   
3.8.4.1. Disruption of porcine carotid artery for TEM imaging 
 
To determine the disruption of the artery due to elastase treatment, the arteries were 
prepared for imaging by TEM.  Following either elastase or saline infusion (described in 
Section 3.8.4), the arteries were cut into small segments (~3 mm in length) and placed in 
room temperature 4% paraformaldehyde and incubated at 37°C for 5 minutes before 
fixation overnight at 4°C.  The samples were post-fixed in 1% w/v osmium tetroxide (1 
hour), dehydrated in a graded ethanol series (50-100% v/v), embedded in Epon 812 resin, 
sectioned, placed on copper grids, stained with uranyl acetate and lead citrate, and imaged 
(using FEI Tecnai G2 Spirit) under multiple magnifications.   
3.8.4.2 Targeting cathepsin K modified NPs to the matrix-injured artery wall 
 To determine the effectiveness of cathepsin K targeting in the aorta, thawed porcine 
arteries (n = 3) were infused with elastase (20 units/ml, 37 °C, 20 minutes, Sigma) and 
rinsed with PBS.  Following elastase infusion, unmodified Alexa Fluor 633-loaded NPs, 
cathepsin K Ab-conjugated Alexa Fluor 633-loaded NPs, IgG Ab-conjugated Alexa Fluor 
633-loaded NPs, or 0.9% saline were infused in the artery (1 ml, 2 mg/ml NP) and 
incubated (37°C, 20 minutes).  Following incubation, the arteries were flushed with PBS 
to remove any unbound NPs.  The arteries were imaged (IVIS Spectrum CT In Vivo Imager, 
PerkinElmer; Waltham, MA) and analyzed using spectral unmixing to measure NP binding 
using Living Image® software.  Briefly, spectral unmixing was used to subtract tissue 
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autofluorescence from each sample to allow for pure AF633 NP fluorescent signal.  Once 
the tissue autofluorescence was removed, ROIs were drawn over each artery and the total 
radiant efficiency ([p/s]/ [µW/cm2]) was measured and the fold-increase of NP 
fluorescence was calculated. 
3.9. Characterizing DOX release from cathepsin K Ab-conjugated and 
unconjugated NPs 
 
 DOX release from both cathepsin K Ab-conjugated and unconjugated NPs was 
measured in PBS at 37oC.  The efficiency of DOX encapsulation within the NPs was 
determined by pooling the supernatants from the washing and ultracentrifugation steps for 
individual NP formulations.  Unencapsulated DOX in the supernatant fraction was assayed 
by UV spectrophotometry (SpectraMax M2, Molecular Devices, Inc., Sunnyvale, CA) 
using the absorbance peak of DOX at 270 nm. This peak was calibrated to a standard curve 
generated using serial dilutions of a 1 mg/mL DOX solution.  The total amount of 
encapsulated DOX and the encapsulation efficiency were determined by subtracting the 
total amount of unencapsulated DOX from the known amount of DOX added during NP 
formulation.  Aliquots containing conjugated or unconjugated DOX-NPs (0.5 mg/ml) were 
collected at various time points over 45 days and centrifuged (13,000 rpm, 30 min, 4oC).  
The amount of DOX in the supernatant was quantified by UV spectrophotometry.  The 
absorbance at  = 270 nm was calibrated to a standard curve generated using serial dilutions 
of DOX in PBS. Following the absorbance measurements, the volume in each sample was 
replenished with fresh PBS.  The total amount of DOX loaded in the NPs was calculated 
and the released amount was used to determine the percentage of DOX released.    
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3.10. DNA assay for cell proliferation 
 
The DNA content of the cell layers was measured via a fluorometric assay of 
Labarca and Paigen to determine the combined effects of the unconjugated or conjugated 
NPs and released DOX on EaRASMC proliferation111. The cell layers were harvested at 1 
and 21 days of culture in Pi buffer, sonicated on ice, and assayed for DNA content. Cell 
density was calculated assuming 6 pg of DNA per cell.  
3.11. Fastin assay for elastin 
 
A Fastin assay (Accurate Scientific and Chemical, Westbury, NY) was used to 
quantify the amounts of elastic matrix (alkali-soluble and insoluble fractions) deposited by 
EaRASMCs. For each of 3 replicate samples, cell layers from 3 separate wells were 
harvested in Pi buffer, at 21 days of culture, and pooled.  The cell layers were homogenized 
by sonication on ice.  The cell suspension obtained was digested with 0.1 N NaOH (1 h, 
98 ºC) and then centrifuged to yield a pellet containing mature, highly cross-linked alkali-
insoluble elastin and a supernatant fraction containing less cross-linked alkali-soluble 
elastin. The alkali-insoluble elastin was converted into a soluble form prior to 
quantification, as the Fastin assay can only quantify soluble α-elastin.  The pellet obtained 
after the NaOH digestion step was dried and solubilized with 0.25 M oxalic acid (1 h, 95 
ºC), then pooled and centrifuge-filtered (3000 rpm, 10 min) in microcentrifuge tubes 
(Amicon® Ultra, 10 kDa molecular weight cut-off; Millipore, Inc., Billerica, MA).  The 
alkali-soluble and insoluble matrix elastin fractions, as well as the tropoelastin precursors 
released into the cell culture medium were then measured using the Fastin assay. The 
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amounts of elastin measured were also normalized to the corresponding DNA amounts, so 
as to provide an accurate comparison between the different treatments. 
3.12. Elastic matrix ultrastructure visualized by transmission electron microscopy 
(TEM) 
 
 To visualize the ultrastructure of deposited elastic matrix, EaRASMCs were seeded 
into permanox chamber slides (Thermo Fisher; Waltham MA; 50,000 cells per well) and 
stimulated with 50 ng/ml of TNF-α.  After 21 days of culture, the test (cathepsin K Ab-
conjugated DOX-loaded NPs, unconjugated DOX-loaded NPs) and control EaRASMC 
cultures were rinsed with PBS (37 °C) and fixed (5 min, 37 °C, 4% w/v 
paraformaldehyde/2.5% w/v glutaraldehyde prepared in 0.1 M sodium cacodylate buffer).  
Following the initial fixation step, the cell layers were incubated in the fixative overnight 
at 4 °C.  The samples were post-fixed in 1% w/v osmium tetroxide (1 hour), dehydrated in 
a graded ethanol series (50-100% v/v), embedded in Epon 812 resin, sectioned, placed on 
copper grids, stained with uranyl acetate and lead citrate, and imaged (using FEI Tecnai 
G2 Spirit) under multiple magnifications.    
3.13. Assessing MMP-2 and -9 expression in DOX-loaded NP treated EaRASMCs 
 
 MMP-2 and -9 expression by EaRASMCs cultured with cathepsin K Ab-
conjugated or unconjugated DOX-NPs were compared using western blots. At 21 days of 
culture, the cell layers were harvested in RIPA buffer with protease inhibitor and 3 wells 
were pooled per replicate (n = 3 replicates/treatment). Maximum volumes of sample 
protein (15.6 µL) were then loaded under reduced conditions into each lane of a 10% Bis-
Tris electrophoresis gel (Invitrogen), along with a SeeBlueTM pre-stained molecular weight 
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ladder (Invitrogen) and MMP-2 and -9 standards. The gels were run in MOPS buffer 
(Invitrogen) for 50 minutes at 200 V, and subsequently dry transferred onto nitrocellulose 
membranes (iBlot® Western Blotting System, Invitrogen). As before, the membranes were 
blocked with Odyssey Blocking Buffer for 1 hour and immunolabeled (4 oC, overnight) 
with a rabbit polyclonal antibody against MMP-2 (1:500 dilution; Abcam, Cambridge, 
MA) or rabbit monoclonal antibody against MMP-9 (1:500 dilution; Millipore, Billerica, 
MA) with a mouse monoclonal antibody against β-actin (1:1000 dilution; Sigma-Aldrich) 
as a loading control. Secondary labeling occurred for 1 hour at room temperature using 
IRDye® 680LT goat-anti-rabbit (1:15,000 dilution; LI-COR Biosciences) and IRDye® 
800CW goat-anti-mouse (1:20,0000 dilution; LI-COR Biosciences). A LI-COR Odyssey 
laser scanner was used to quantify the fluorescence of the secondary antibodies. The 
intensities of the active MMP-2 and MMP-9 bands on all gels were quantified using ImageJ 
software, expressed in terms of relative density units (RDU) and normalized to the intensity 
of their respective β-actin bands to enable comparison between the different test cases 
within the same blot. The ratios obtained for the NP-supplemented cell layers were further 
normalized to that for standalone EaRASMC cultures (treatment controls). 
3.14. Assessing MMP-2 and -9 activity using gel zymography 
 
 The differential effects of cathepsin K Ab-conjugated and unconjugated DOX-
loaded NPs on enzyme activity of MMP-2 and -9 in EaRASMC cultures was assessed using 
gel zymography. Cell layers harvested in RIPA with a protease inhibitor were loaded into 
each lane of a 10% zymogram gel (Invitrogen) in a volume containing 5 μg of protein, 
along with a SeeBlueTM pre-stained molecular weight ladder, and MMP-2 and -9 protein 
standards. Gels were run for 2 h at 125 V. The gels were then washed in a buffer containing 
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2.5% v/v Triton-X-100 for 30 min to remove sodium dodecyl sulfate (SDS) detergent, and 
then incubated overnight in a substrate/development buffer to activate the MMPs.  The gels 
were stained with Coomassie Brilliant Blue solution for 45 min, and destained for 90 min, 
until clear bands appeared visible against the blue background of the gel. Band intensities 
(RDU) of the bands obtained for NP-supplemented cultures were measured using ImageJ 
software, and normalized to those obtained for the NP-untreated control cultures to 
determine fold changes in MMP activity. Data was acquired from 3 independent replicate 
gels.  
3.15. Verification of cadherin and αvβ3 expression and targeting by Ab-modified 
NPs 
 
3.15.1. Cadherin and αvβ3-Integrin expression by HUVECs in culture  
 
 In order to actively target the SMCs in the aorta, it is crucial for the NPs to pass 
through the endothelial cell layer.  In AAAs, the endothelial cell layer is disrupted leading 
to gap formation and a leaky endothelium.  Cadherin plays a vital role in cell-to-cell 
junctions so a decrease in cadherin expression can lead to the gap formation.  Human 
umbilical vein ECs (HUVECs) were seeded at 30,000 cells per well and incubated at 37 
°C until a confluent layer was formed.  The cells were stimulated with 10 ng/ml TNF-α for 
24 hours at 37°C.  Following stimulation, cells were fixed with 4% paraformaldehyde (10 
minutes, RT) and washed 3 times with PBS.  The cell layer was blocked with the 
appropriate serum (5% serum, 20 minutes, RT).  Following blocking, the primary antibody 
(1:100 dilution of cadherin Ab or αvβ3 Ab) was added and incubated overnight at 4 °C.  
The primary antibody solution was aspirated and the cell layer washed with PBS.  The 
secondary antibody (AF 488-conjugated secondary antibody, 1:1000 dilution) was added 
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and incubated for 1 hour at room temperature.  The secondary antibody solution was 
aspirated and the cell layer washed with PBS twice.  The cell layers were mounted onto 
glass coverslips using VectaShield® with DAPI to stain the nucleus.  After mounting, the 
cell layers were visualized using a fluorescent microscope.    
3.15.2. Preparation of AF633-loaded NPs 
 
 The AF633-loaded NPs were prepared using the methods previously described in 
Section 3.4.  The PLGA NPs were prepared using a double emulsion solvent evaporation 
method with the AF633 encapsulated within the NP followed by washing to remove 
unencapsulated dye, flash freezing, and lyophilization to produce a dry powder.  The 
particle size and surface zeta-potential were determined using a commercial particle-sizing 
system (PSS/NICOMP 380/ZLS, Particle Sizing Systems; Santa Barbara, CA) as described 
in Section 3.5.   
3.15.3. Preparation of αvβ3-integrin Ab-modified NPs 
 
The αvβ3-integrin plays a vital role in cellular adhesion and migration as well as 
cellular uptake.  The goal of incorporating the αvβ3-integrin onto the NP surface was to 
increase the movement of the NPs through the endothelial cell (EC) layer into the tunica 
media.  The covalent binding of the αvβ3-integrin Ab to the NP surface was performed 
using the procedure described previously in section 3.6.2 for cathepsin K Ab incorporation.  
The NPs were suspended in MES (0.5 mg/ml) and incubated with 10 µl of αvβ3-integrin 
Ab and 100 ng EDC for 5 hours.  After incubation, the NPs were rinsed with PBS twice.   
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3.15.4. Assessment of αvβ3-integrin Ab incorporation on NP surface 
 
Using the previously described procedure for measuring Ab binding to NPs 
(Section 3.7.3) we determined binding of the αvβ3-integrin Ab.  An Alexa Fluor (AF) 488-
conjugated goat anti-rabbit secondary Ab (1:1000 dilution; Thermo Fisher), was used to 
fluorescently tag the NP-bound αvβ3-integrin Ab (25 C, 1 hour).  Three 150 µl aliquots 
per sample were added to a microplate and the fluorescence of both the fluorescein (λex = 
493 nm and λem = 525 nm) and Alexa Fluor 633 (λex = 632 nm and λem = 647 nm) were 
measured using a microplate reader.  The NPs were aliquoted onto glass cover slips, 
mounted, and visualized on a fluorescent microscope.   
3.15.5. NP localization in HUVEC cultures 
 
 HUVECs were seeded onto glass coverslips at a density of 30,000 cells per well 
and incubated for 7 days.  The cells were unstimulated or stimulated with TNF-α (10 ng/ml) 
for 24 hours before the addition of AF633-loaded NPs or αvβ3 Ab-modified AF633-loaded 
NPs.  The test cases are shown in Table 3.3.   
Table 3.3. Test cases for localization of NPs in HUVECs. 
Stimulation Nanoparticle 
TNF-α αvβ3 Ab Modified 
No TNF-α αvβ3 Ab Modified 
TNF-α Unmodified AF633 NPs 
 
The cells were incubated with the NPs for 3 hours at 37 °C followed by washing 
with PBS to remove any unbound NPs.  A membrane stain (Vybrant® DiI Cell-Labeling 
Solution, Thermo Fisher Scientific, 40 µM) was added to the cell layer and incubated for 
15 minutes at 37 °C.  The DiI solution was aspirated and the cell layer washed with PBS.  
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Following membrane staining, the cells were fixed with 4% v/v paraformaldehyde (10 
minutes, RT) and mounted onto slides with mounting medium containing DAPI stain 
(VectaShield® mounting medium with DAPI).  The cell layers were imaged using a 
confocal microscope (Leica TCS SP5 II-AOBS, Buffalo Grove, IL) allowing for the 
generation of Z-stacks enabling 3D reconstruction and multiple planes of views through 
the entire cell layer.      
3.16. Migration of NPs through endothelial cell layer 
 
3.16.1. FITC-Dextran migration through endothelial cell layer 
 
 HUVECs were seeded on a transparent 1.0 µm polyethylene terephthalate (PET) 
membrane cell insert that had been previously coated with collagen.  Rat Tail Collagen 
Type I (1 mg/ml) was added to the membrane and incubated for 1 hour at 4 °C.  The 
collagen solution was removed and the membranes incubated overnight at 4 °C.  After 
incubation, HUVECs were seeded (30,000 cells per insert) on each membrane and allowed 
to incubate at 37 °C for 7 days.  The test case was HUVECs stimulated with TNF-α (10 
ng/ml) for 24 hours and the two control cases were HUVECs without stimulation and the 
membrane containing no HUVECs.  FITC-Dextran (1 mg/ml, 150,000 avg. MW) was 
added to the upper chamber of each insert and incubated at 37 °C for 3 hours.  Following 
incubation, the supernatant from the lower chamber was removed and three 150 µl aliquots 
from each sample were added to a 96-well microplate and the fluorescence measured using 
a fluorescent plate reader (λex = 490 nm and λem = 525 nm).   
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3.16.2. NP migration through the endothelial cell layer 
 
 AF633 loaded-NPs were modified with an αvβ3-integrin Ab as previously described 
(Section 3.15.3).  HUVECs were seeded on a 1.0 µm PET membrane cell insert previously 
coated with collagen using the procedure from Section 3.16.1.  The test cases were 
stimulated with TNF-α (10 ng/ml) for 24 hours.  Following stimulation, the αvβ3-integrin 
Ab-modified NPs or unmodified NPs (0.2 mg/ml) were added to the upper chamber of the 
insert (Table 3.4).  The cells were incubated for 3 hours at 37 °C.  Following incubation, 
the media from the lower chamber was removed and the fluorescence of the NPs was 
measured using a fluorescent plate reader (λex = 632 nm and λem = 647).    
Table 3.4 Test cases for NP migration through the endothelial cell layer. 
Cells Stimulation NP Addition 
Yes TNF-α (10 ng/ml) αvβ3-integrin Ab-modified AF633 NPs 
Yes TNF-α (10 ng/ml) Unmodified AF633 NPs 
Yes No TNF-α Unmodified AF633 NPs 
No No TNF-α Unmodified AF633 NPs 
 
3.17. Oxidative stress assay for DOX-loaded NPs in HUVECs and EaRASMCs 
 
 In order to determine the toxicity of DOX-loaded NPs, the oxidative stress and 
superoxide production was measured when DOX-loaded NPs were cultured with 
EaRASMCs and HUVECs.  The oxidative stress was determined using an ROS/Superoxide 
Detection Assay Kit (Abcam).  Cells were seeded in a 96 well plate at a density of 20,000 
cells per well and incubated at 37°C until the cells were at ~70-80% confluency 
(approximately 48 hours).  The media was aspirated and fresh media added the day of the 
experiment.  The cells were simultaneously treated with DOX-loaded NPs (0.2 mg/ml) and 
100 µl of ROS/Superoxide Detection Solution (1:2500 dilution of Oxidative Stress 
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Detection Reagent, 1:2500 dilution of Superoxide Detection Reagent).  The cells were 
incubated for 60 minutes at 37°C.  Following incubation, the plate was read from the 
bottom using a fluorescent plate reader for fluorescein (λex = 488 nm and λem = 520 nm) 
and rhodamine (λex = 550 nm and λem = 610 nm).  
3.18. AAA induction in rat model via periadventitial elastase injury  
 
3.18.1. Surgical procedure for AAA induction  
 
Previously, as described in Section 3.1, aneurysm induction in our lab was 
performed using an elastase infusion into the aorta which requires complex microsurgical 
intervention for collateral vessel ligation, aortal catheterization and aortotomy sealing, the 
latter at risk of reopening and hemorrhage.  As a result, we investigated if small aneurysms 
could be generated in the rat model instead through periadventitial elastase treatment.  This 
method also provides the advantages of limiting lower limb paralysis that results from 
extended durations of surgery.   
All rat surgeries were performed with IACUC approval at the Cleveland Clinic 
(2016-1581).  Acepromazine (0.5 mg/kg) was administered subcutaneously approximately 
30 minutes before the induction of anesthesia.  Fresh elastase solution was prepared (20 
Units or 40 Units elastase, Sigma) and stored on ice until use.  Immediately before 
anesthesia induction, buprenorphine hydrochloride (0.03 mg/kg) was administered 
subcutaneously.  Following injection, the rat was moved to the anesthesia induction 
chamber (oxygen flow rate 1 L/min, 2.5% v/v isoflurane) for 7-8 minutes until 
anesthetized.   
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Once anesthetized, the rat was removed from the chamber and ophthalmic eye 
ointment was applied to both eyes.  The rat was placed on the surgery table and its nose 
inserted into the nose cone.  The isoflurane concentration was reduced to 2% for the 
duration of the procedure.  The hair from the abdomen was clipped, the abdominal skin 
sterilized using betadine and alcohol scrubs with application proceeding from the inside 
out.  Immediately before the surgical procedure, 0.25% Bupivacaine (2-8 mg/kg; analgesic) 
was administered subcutaneously at the incision site.  The abdominal cavity was exposed 
by a laparotomy and the abdominal wall was held open using retractors.  The exposed 
intestines and other internal organs (stomach, pancreas, liver, etc.) were removed to outside 
the body cavity and were covered with moistened sterile gauze to prevent drying during 
the procedure.  Using fine forceps, the aorta was exposed by removing surrounding fat and 
connective tissue.  Once the aorta was exposed, images were taken using a microscope to 
allow for diameter determination.  The elastase or 0.9% v/v saline was soaked up by a small 
piece of gauze and the soaked gauze was placed around the aorta.  This was done to ensure 
the treatment stayed in contact with the aorta for 20 minutes.  The gauze was removed and 
the residual solution (elastase or saline) removed by rinsing the cavity with sterile saline 
and soaked up with sterile gauze.  Images of the aorta were taken post treatment.  The 
intestines were replaced and the abdomen sutured.  The muscle layer was sutured using 4-
0 vicryl non-absorbable nylon stiches in a running pattern.  The skin was sutured using 4-
0 silk stiches in an interrupted pattern.  During suturing, the isoflurane was reduced to 1.5% 
v/v to begin recovery.   
The animal was removed from isoflurane and placed on a heating pad (37 °C) to 
continue recovery.  The animal was moved to its cage and placed on a towel to finish 
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recovering.  While in the cage, food and a water-gel pack was placed on the cage floor to 
allow access during recovery.  Once the animal has recovered enough to move around the 
cage, the cage was returned to the BRU.  Pain from the surgery is managed through twice 
daily injections of buprenorphine hydrochloride (0.03 mg/kg) for 72 hours.  
3.18.2. Rat AAA diameter measurements using stereomicroscope 
 
 The images taken prior to elastase treatment were used for diameter measurements 
of the aorta.  All images of the aorta during surgery were generated using an Olympus 
SZ61 microscope.  The images include a reference marker with a known diameter (1.5 
mm) to accurately measure the aorta diameter.  To perform the measurements (ImageJ®), 
a straight line was drawn across the reference marker to determine the number of pixels 
per 1.5 mm and this was used to create a global scale.  Straight lines were drawn across six 
different segments of the exposed aorta and the length of each line was calculated.  The 
average length and standard deviation of the lines were calculated for each rat.  The same 
procedure was used to determine the final diameter of the aorta following a 14 day 
development period.  The initial and final measurements were compared to determine the 
increase in diameter due to the elastase treatment.   
3.18.3. Rat AAA model for aorta imaging using MRI  
 
 An initial trial for protocol development was set up to optimize the MRI parameters 
to clearly visualize the aorta.  This protocol development was performed on a naïve male 
rat under anesthesia.  The breathing rate of the rat was monitored and the concentration of 
isoflurane administered was altered to maintain 50 breaths per minute.  The breathing rate 
was maintained at this level due to the MRI software containing a specific gated imaging 
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program that generates clearer images.  This MRI program takes images between breaths 
to minimize the distortion effects of the movement of the chest cavity.   
The anesthetized rat was placed in the MRI in a prone position for imaging.   
Multiple images of the abdomen were taken to identify which parameters and program 
settings generated clear visualizations of the aorta.  The images were taken under several 
imaging modes including T1-Flash, T1-FISP-3D, and T2-TurboRARE.  The images were 
taken with either a coronal or axial orientation.   
To further develop the imaging protocol, a euthanized rat, which had undergone 
aneurysm induction as previously described (Section 3.18.1), was imaged to determine 
aorta diameter.  For this protocol development, the rat was placed in the MRI instrument 
in a supine position.  The change in position (prone to supine) was taken into account to 
determine which position enhances the images.  Images were taken using T1-Flash and T2-
TurboRARE.   
All images from the MRI were converted from a DICOM format to a NiFTi format 
for use in imaging software.  The images were viewed using the software programs mricron 
and MIPAV to visualize the aorta, determine aorta diameter, and generate a 3D 
reconstruction.  In MIPAV, the aorta was measured using the line tool to draw a line across 
the aorta and the width measured from the line length.  The aorta was measured in two 
directions – from the coronal plane and the sagittal plane to determine any expansion from 
periadventitial elastase treatment.   
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3.18.4. Cathepsin K expression in induced rat AAAs  
 
Following aneurysm induction, the aneurysm was left to develop over 14 days 
before sacrificing the rat by CO2 and a physical secondary method.  The abdomen of the 
euthanized rat was opened using sterile procedures through the previously described 
laparotomy and the aorta exposed.  Healthy segments and elastase injured segments of the 
aorta were removed and rinsed with PBS.  Removing healthy and injured segments from 
the same aorta provides an internal control for cathepsin K expression.  The segments were 
flash frozen in liquid nitrogen and stored at -80°C before lyophilization.  The dried 
segments were placed in RIPA buffer, homogenized and placed on a shaker at 4 °C for 1 
hour.  The vials were centrifuged (12,000 rpm, 10 min) to pellet any debris and the 
supernatant collected.  The supernatant was stored at -80°C until western blot was 
performed.  The western blot for cathepsin K expression was performed following the 
procedure previously described (Section 3.8.2). 
3.18.5. Preliminary imaging studies to assess uptake of intravenously infused NPs into 
AAA wall 
 
 Following aneurysm induction and development, the rat was anesthetized using 
isoflurane (2.5%).  The abdomen and back of the rat were shaved to decrease auto 
fluorescence before imaging.  The rat was placed in a prone position in the IVIS Spectrum 
CT connected to isoflurane to maintain anesthesia during imaging.  Images of the 
anesthetized rat were taken under varying wavelengths as a control and to allow for spectral 
unmixing.  The multiple wavelengths were selected to cover the excitation and emission 
wavelengths of the AF633 loaded into the NPs as well as allow for the subtraction of tissue 
autofluorescence.  Following the collection of control images, the anesthetized rat was 
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injected with cathepsin K Ab-modified AF633 NPs (5 mg/ml) via tail vein injection.  
Images were taken at 30 minutes, 3 hours, and 24 hours post-injection to determine the 
localization of the NPs.   
 Following aneurysm induction and development, the rat was anesthetized (2.5% 
isoflurane) and injected with cathepsin K Ab-modified VivoTag® 800-loaded NPs (10 
mg/ml) via tail vein injection.  The rat was euthanized after injection (1 or 3 hours) and the 
abdomen opened via laparotomy to expose the aorta.  The exposed aorta was imaged using 
the IVIS Spectrum CT to determine the localization of the NPs.  As previously discussed, 
the images were taken under multiple wavelengths to visualize the fluorescently loaded 
NPs as well as identify background and tissue autofluorescence.  The images were 
visualized using Living Image® software and spectral unmixing was performed to identify 
pure Vivotag800® fluorescence.   
3.19. Statistical analysis 
 
All experimental data presented (n = 3 per condition, unless stated otherwise) are 
mean values with standard deviation (SD) or standard error (SE) where indicated. 
Statistical significance of differences between mean values for different samples and 
conditions was evaluated using a Student’s t-test, with p ≤ 0.05 considered as statistically 
significant.   
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CHAPTER IV 
RESULTS AND DISCUSSION 
 
4.1. Introduction 
 
 The following sections present the results from experiments conducted to 
demonstrate the feasibility of using cathepsin K as a molecular target for AAA wall-
specific delivery of drug-releasing elastic matrix regenerative NPs.  The experiments assess 
the formulation of Ab-modified NPs, expression of cathepsin K in vitro and ex vivo, and 
the ability of cathepsin K Ab-conjugated NPs to target cathepsin K.  The ability of Ab-
conjugated NPs to migrate through the endothelial cell layer is discussed as well as the 
stress induced from the presence of iron oxide NPs.  Finally, aneurysm induction in a rat 
model, experiments to identify and image aneurysm formation, and the ability of Ab-
conjugated NPs to target the aneurysm is discussed.    
4.2. Formulation and characterization of PLGA nanoparticles  
 
 The physical characteristics, size and zeta potential, of the 0.25% w/v DMAB 
stabilized PLGA NPs were determined for the various encapsulations.  The formulation of 
the blank PLGA NPs stabilized with DMAB exhibited a size of 306.9±115.1 nm and a zeta 
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potential of 30.89 mV.  Changing the loading of the NPs with either 2% DOX or various 
fluorescent dyes did not affect the size or zeta potential (Table 4.1).  For the NPs in this 
study, the target size was ~300 nm and the target zeta potential was ~30 mV.   
Table 4.1.  Mean size and zeta potential of DMAB stabilized PLGA NPs with various 
encapsulations.   
NP Condition Size (nm) ζ-potential (mV) 
No encapsulation 306.9±115.1 30.89 
2% w/w fluorescein 280.9±96.4 30.29 
2% w/w DOX 299.3±124.8 32.04 
2% w/w Alexa Fluor 633 287.8±90.4 40.52 
2% w/w VivoTag® 800 343.1±147.9 29.00 
 
4.3. Cathepsin K Ab-modified NPs 
 
4.3.1. Assessment of cathepsin K Ab conjugation to NPs 
 
 The conjugation of the cathepsin K Ab to the surface of the NPs was confirmed 
using fluorescence microscopy (Figure 4.1).  Utilizing the adsorption and covalent 
conjugation methods, the cathepsin K was successfully incorporated on the NP surface 
(Figure 4.1.B and Figure 4.1.C).  Incubation of the NPs with the cathepsin K Ab for 5 
hours was appropriate as longer incubation times (up to 24 hours) did not result in improved 
Ab conjugation (Figure 4.1.A)112.   
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Figure 4.1.  The effect of incubation times on conjugation of the antibody to NPs (A). The 
cathepsin K antibody was detected with a fluorescein-tagged secondary Ab. Relative 
abundance of conjugated antibodies on the NP surface (B). Cathepsin K antibodies were 
conjugated onto fluorescein-loaded NPs over 5 hours and were detected with secondary 
antibodies tagged with AF546.   Values shown indicate mean ± SD of RFUs (A) or of ratios 
of RFUs due to the fluorescein and AF546; n = 3 per case; # denotes significance of 
differences versus 2 h of incubation, deemed for p < 0.05 ; * denotes significance of 
differences versus control FITC NPs treated with the AF-546-tagged secondary antibody, 
deemed for p< 0.05. In C, micrographs compare cathepsin K antibody bound to NPs via 
adsorption and covalent conjugation methods (see quantitative data B). Conjugation was 
performed over 5 hours. Fluorescein (green) was encapsulated within the NPs and the 
cathepsin K antibody was detected with an AF546-tagged secondary antibody (red).  Panel 
C1 shows lack of red auto-fluorescence from cathepsin K antibody-conjugated NPs not 
treated with the AF546-tagged secondary antibody. Panels C2 and C3 show that cathepsin 
K antibody was successfully conjugated to the NP surface using the adsorption and 
covalent binding methods respectively112. 
 
In Figure 4.1.C, unconjugated NPs (A) fluoresce green and the cathepsin K Ab-conjugated 
NPs with the AF546 fluorescent secondary antibody (B) fluoresce yellow.  The AF546 
secondary antibody fluoresces red alone but when the red and the green signals overlap, 
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the fluorescent signal turns yellow.  The overlapping of these signals and the yellow 
fluorescence present in the images confirms the conjugation of the cathepsin K Ab to the 
NP surface.   
4.3.2. Assessment of cathepsin K Ab modification for covalent and adsorption methods 
 
 To determine whether the covalent conjugation method or the adsorption method 
provided a stronger cathepsin K Ab attachment to the NP surface, fluorescence microscopy 
was used (Figure 4.2).  The adsorption method for Ab attachment to the NP surface utilizes 
van der Waals forces, generally a weak force, while the covalent conjugation involves a 
carbodiimide reaction to generate covalent bonds between the Ab and surface.  Images 
were taken under similar conditions at day 1 and day 14.  The intensity of the AF633-
loaded NPs (red) were measured as well as the intensity of the FITC-labeled cathepsin K 
antibody (green).  The fluorescence of the NPs in Figure 4.2.A show a noticeable change 
in FITC fluorescence at day 14 for the adsorption method.  To quantify the changes in 
fluorescence intensity, the corrected total fluorescence was calculated and a ratio of FITC 
to AF633 was determined.  Figure 4.2.B shows the conjugation method provides a 
significantly (p < 0.05) more robust attachment of the cathepsin K Ab to the NP surface.  
After 14 days, there was a significant decrease in cathepsin K Ab presence on the NP 
surface for the adsorption method.  However, there was no significant loss of cathepsin K 
Ab from the NP surface at 14 days, when covalently conjugated.  This confirms the 
covalent conjugation method, which generates stronger covalent bonds compared to the 
weaker van Der Waals interactions, is superior to the adsorption method and therefore will 
be used in following experiments.   
80 
 
 
Figure 4.2. Panels A and B show results of fluorescence microscopy analysis of cathepsin 
K surface modification to AF633-loaded NPs (red).  A fluorescein antibody (green) was 
added to visualize the cathepsin K modification.  Panel A shows representative images for 
the adsorption and covalent conjugation methods at day 1 and day 14.  The green 
fluorescence demonstrates successful cathepsin K conjugation to the NP surface.  At day 
14, green fluorescence associated with NPs modified using Ab-adsorption was much lower 
compared to NPs covalently conjugated with the Abs.  Panel B shows the ratio of FITC 
intensity to AF633 intensity (mean ± SE; adsorption n=132, n=130 and conjugation n=154, 
n=207).  The conjugation method bound more cathepsin K to the NP surface for a longer 
period of time.  # denotes significance of differences between adsorption and conjugation 
on day 14 deemed for p<0.05.  * denotes significance of differences between day 1 and 
day 14 for the adsorption method deemed for p<0.05112.   
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4.4. Verification of cathepsin K overexpression 
 
4.4.1. Verification of cathepsin K expression in EaRASMCs 
 
Increased expression of cathepsin K by EaRASMCs and the effects of TNF-α in 
augmenting the expression were investigated as this simulates the AAA environment.  
Comparing cathepsin K expression levels between healthy SMCs (RASMCs) and 
EaRASMCs, the stimulation of EaRASMCs with TNF-α increased the expression of 
cathepsin K significantly (Figure 4.3.A and Figure 4.4).  Figure 4.4 highlights the 
increased cathepsin K expression using western blot and the images in Figure 4.3.A show 
an increase in cathepsin K expression within the cell layer but it does not provide enough 
information to determine the location of the cathepsin K.  In order for the cathepsin K Ab-
conjugated NPs to target cathepsin K, it needs to be released from the cells and localized 
on the cell surface.  To determine the localization of cathepsin K, IF labeling for cathepsin 
K was visualized using a confocal microscope and reconstructed in 3D (Figure 4.3.B-C).  
Figure 4.3.B shows the 3D reconstruction of the cell layer with the nuclei (blue), actin 
filaments (green) and the cathepsin K (red).  The image in Figure 4.3.B is a representative 
image of the cell layer and shows the aggregation of cathepsin K on the cell surface.  
However, for further confirmation of cathepsin K localization, the cell layer was imaged 
at various planes heights (Figure 4.3.C.1 through 4).  Figure 4.3.C.1 shows the bottom of 
the cell layer which was attached to the glass coverslip.  This region shows very little 
cathepsin K present.  As the imaging planes move towards the top of the cell layer (Figure 
4.3.C.2 through 3), cathepsin K begins to appear.  This confirms the presence of cathepsin 
K on the cell surface and therefore it can be utilized as a target molecule for the cathepsin 
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K Ab-conjugated NPs.  Figure 4.3.C.4 is a graphical representation of the plane heights 
shown in C.1 through C.3. 
 
 
Figure 4.3. (A) IF images (20x) showing relative expression of cathepsin K in RASMCs 
and EaRASMCs, without and with TNF-α stimulation. Cathepsin K (AF546-tagged 
secondary antibody) appears red while the cytoskeletal actin filaments (AF488 phalloidin) 
appear green, and DAPI-stained nuclei appear blue. (B) High magnification view of 
EaRASMCs stimulated with TNF-α and cathepsin K visualized with AF546-tagged 
secondary antibody and cytoskeletal actin stained with AF488 phalloidin. Grid: 23 µm x 
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23 µm. (C). Images of the EaRASMCs at different z-axis heights.  (1) The bottom of the 
cell layer which shows minimal cathepsin K. (2) The middle of the cell layer in which 
cathepsin K begins to appear.  (3) The top of the cells where the most cathepsin K is found. 
Scale bar for C.1-3:  50 µm. (4) Schematic of the z-axis heights for images C.1-3112.   
 
 
Figure 4.4. Western blot analysis for relative expression of cathepsin K by healthy and 
aneurysmal SMCs, with and without TNF-α stimulation. The figure shows a representative 
blot, indicating bands for the cathepsin K zymogen and β-actin (loading control). The plot 
shows -actin normalized cathepsin K band intensity (mean ± SD; n = 3 per case); * 
denotes p < 0.05 compared to TNF--unstimulated EaRASMCs. # indicates significance 
of differences versus RASMCs, deemed for p < 0.05112. 
 
4.4.2. Verification of cathepsin K expression in elastase injured arteries 
 
Differences in cathepsin K expression in healthy and matrix-injured porcine carotid 
arteries was investigated to rationalize using cathepsin K as an NP target in the AAA wall, 
wherein such elastase induced matrix disruption occurs.  Elastase has the ability to digest 
elastin fibers causing injury similar to an abdominal aortic aneurysm.  Western blot 
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analysis (Figure 4.5) showed significant increase in active cathepsin K (38 kDa) 
expression after exposure to elastase compared to the saline control (7.85 ± 1.93 vs. 0.14 
± 0.02, p < 0.05).  These findings are similar to our previous results showing an increased 
cathepsin K expression in TNF-α activated EaRASMCs cultures.  The increase in cathepsin 
K provides a rationale for the study of elastase injured arteries in the context of 
investigating targeted binding of cathepsin K Ab-conjugated NPs.    
 
Figure 4.5.  Verification of the expression of cathepsin K Ab in elastase injured carotid 
arteries compared to saline treated arteries, assayed using western blots.  Panel A shows a 
representative blot, showing the active cathepsin K form (38 kDa) and β-actin (loading 
control).  Panel B shows β-actin normalized cathepsin K band intensity (mean ± SEM; n = 
9 per case; # denotes significance of difference, deemed for p < 0.05112. 
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4.5. Targeting of Ab-conjugated NPs to cathepsin K expressing cells 
 
4.5.1. Targeting of cathepsin K Ab-conjugated NPs in EaRASMCs 
 
Figure 4.6 shows microscope and confocal images of RASMCs and EaRASMCs, 
cultured without TNF-α or with TNF-α, exposed to cathepsin K Ab-conjugated NPs (red 
fluorescence).  EaRASMCs stimulated with TNF-α exhibited a high amount of bound, 
cathepsin K-Ab conjugated NPs relative to the RASMCs and the EaRASMCs without 
TNF-α activation. This indicates that the conjugated NPs have a much higher targeting 
ability correlated to the overexpression of cathepsin K in the stimulated cultures. The 
unstimulated EaRASMCs showed an increase in bound NP compared to the RASMCs but 
less than the stimulated EaRASMCs.  The EaRASMCs exhibit basal levels of cathepsin K 
expression and the amount of bound NPs is directly related to the amount of cathepsin K 
expressed.   
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Figure 4.6.  Localization of cathepsin K Ab-conjugated NPs on RASMCs and EaRASMCs 
stimulated with TNF-α. (A) Microscope images showing binding of cathepsin K antibody-
conjugated NPs to EaRASMCs, without and with TNF-α stimulation. All NPs were 
encapsulated with AF633, causing them to fluoresce red. A higher number of NPs bound 
to EaRASMC cultures stimulated with TNF-α compared to unstimulated EaRASMCs. 
Cytoskeletal actin filaments, stained with AF488 phalloidin fluoresce green and DAPI-
stained nuclei appear blue. (B). High magnification image of NP localization to TNF-α 
stimulated EaRASMCs.  (C) Images of EaRASMCs with NPs at various z-axis heights.  
(1) Bottom of cell layer with minimal NP bound.  (2) and (3) Middle layers of the cell 
where NPs begin to appear around the cell. (4) Top of the cell layer where NPs are bound 
to the cell surface.  (5) Schematic of the various z-axis heights for images 1-4.  Scale bars 
represent 50 µm (A), 23 µm x 23 µm (B), and 50 µm (C)112. 
 
4.5.2. Targeting of cathepsin K Ab-conjugated NPs in elastase injured arteries 
 
Figure 4.7 shows fluorescence images of, and a plot highlighting the fold-
differences in binding of unconjugated NPs and Ab-conjugated NPs to the cathepsin K 
expressing wall of porcine arteries.  Previous results have shown an increase in cathepsin 
K expression following elastase injury in porcine carotid arteries.  Utilizing this 
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overexpression, the conjugation of the cathepsin K Ab to the NP surface will increase the 
retention of the NPs within the vessel.  To compare the binding to cathepsin K specifically, 
the NPs were unconjugated and conjugated with a nonspecific IgG Ab.  The nonspecific 
IgG Ab should not increase the retention of the NPs in the vessel as there is no binding 
sites for the Ab.  In Figure 4.7.A.4, there is no fluorescence from the saline treated artery 
and this was used as a negative control to ensure there was no autofluorescence.  The 
fluorescent images in Figure 4.7.A show the greatest intensity in the cathepsin K Ab-
conjugated NPs while the unconjugated and IgG Ab-conjugated NPs show similar 
fluorescent intensities.  Using Living Image® software to perform spectral unmixing and 
the total radiant efficiency, the intensity of the AF633-loaded NPs was determined for each 
artery using the same sized region of interest.  The total radiant efficiency ratio was 
determined using the unconjugated total radiant efficiency and the results are shown in 
Figure 4.7.B.  The plot of the total radiant efficiency confirms the increase in cathepsin K 
Ab-conjugated NP retention in the artery compared to the unconjugated and IgG Ab-
conjugated NP in which these results are similar to the observations in cell cultures.  The 
intensity of fluorescence due to uptake of cathepsin K Ab-conjugated NPs in the artery 
wall was ~2-fold higher relative to that observed for Ab-unconjugated NPs.     
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Figure 4.7.  Targeting of cathepsin K Ab-conjugated AF633-loaded NPs to wall of elastase 
injured porcine carotid arteries.  (A) Pseudocolor of NP localization in elastase treated 
arteries with (1) cathepsin K-Ab conjugated AF633 NPs, (2) unconjugated AF633 NPs, (3) 
IgG-Ab conjugated AF633 NPs, and (4) saline. (B)  Fold difference in binding of cathepsin 
K Ab-conjugated NPs and non-specific IgG conjugated NPs to elastase treated arteries 
compared to binding of unconjugated NPs (mean ± SEM; n = 6 and n = 3 for IgG-Ab 
conjugation)112.   
 
4.6. Effect of conjugated, DOX-loaded NPs on elastic matrix synthesis 
 
 Prior data from our lab indicate DOX concentrations below 5 µg/ml stimulate 
elastic matrix regeneration while maintaining the inhibitory effects on MMPs23.  Using a 
2% w/w DOX encapsulation in PLGA NPs, the released DOX over a 21-day period is less 
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than 5 µg/ml and the elastic matrix deposition significantly increased in cultures treated 
DOX-loaded NPs compared to untreated cultures23,112.  Our own studies showed that 
cathepsin K Ab conjugation to the NPs does not alter the DOX release profile and generated 
near steady-state doses in the desired dose range (Figure 4.8).  The deposition of the elastic 
matrix was quantified using a Fastin assay (Figure 4.9.B) and culturing EaRASMCs with 
DOX-loaded NPs leads to a significant increase in elastin production per cell compared to 
untreated cells.  The TEM results presented in Figure 4.9.C demonstrate that cathepsin K 
Ab-conjugated and unconjugated DOX-loaded NPs increase generation of elastic matrix 
compared to NP-untreated EaRASMC cultures.  While only sparse elastin fibrils and 
microfibrils were seen in the control cultures (Figure 4.9.C.1), significantly greater 
presence of forming elastic fibers associated with amorphous elastin deposits were seen in 
the DOX-loaded NP-treated cultures.  No significant differences in elastic matrix 
deposition were noted between the cultures receiving Ab-conjugated and unconjugated 
NPs.  This is further supported by the data examining the release profile of conjugated and 
unconjugated NPs in which there was no difference in release kinetics112.  MMPs play a 
significant role in the degradation and remodeling of the ECM especially in AAAs, so 
MMP expression and activity was assessed using western blot and gel zymography, 
respectively (Figure 4.10).  The expression of MMP-2 was significantly decreased in 
EaRASMCs cultured with the cathepsin K Ab-conjugated and unconjugated DOX-loaded 
NPs compared to NP-untreated cultures (Figure 4.10.A and Figure 4.10.B).  Similarly, the 
activity of MMP-2 and MMP-9 was significantly decreased in TNF-α stimulated 
EaRASMCs when cultured with the cathepsin K Ab-conjugated and unconjugated DOX-
loaded NPs compared to NP-untreated cells (Figure 4.10.C-F).  
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Figure 4.8. DOX release profiles in vitro from cathepsin K Ab-conjugated and 
unconjugated NPs loaded with 2% w/w DOX (mean ± SD; n = 3 per group)112. 
 
 
 
Figure 4.9.  The proliferation of EaRASMCs is not impacted by culture with DOX-NPs 
(cathepsin K Ab-conjugated or unmodified), although cell proliferation in the cultures 
treated with the Ab-conjugated NPs was significantly lower than that cultured with the 
unmodified NPs (A) (mean ± SD; n = 3 cultures per group; # denotes significance of 
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differences versus unconjugated DOX-NPs, deemed for p< 0.05).  (B) Cathepsin K 
antibody conjugation of DOX-NPs does not alter their pro-elastogenic effects on cultured 
EaRASMCs.  The amount of deposited elastic matrix was normalized to DNA content of 
the respective cell layers (mean ± SD; n =3 cultures per group; # denotes significance of 
differences relative to treatment controls deemed for p < 0.05).  (C) TEM images showing 
effects of cathepsin K Ab-conjugated and unconjugated DOX-NPs on elastic matrix 
deposition in TNF-α stimulated EaRASMC cultures. Elastic matrix deposition was sparse 
in the (1) NP-untreated cultures and few amorphous elastin deposits and no mature fibers 
were seen. Numerous forming elastic fibers were seen in the NP-treated cultures (2), with 
a greater number of amorphous elastin deposits (white arrows) associated with the 
microfibril components in the cultures that received (3) cathepsin K Ab-conjugated DOX-
NPs. Scale bars: 1 µm112.  
 
Figure 4.10. Panels A and B show the effects of unconjugated and cathepsin K Ab-
conjugated DOX-NPs on MMP-2 protein synthesis in TNF-α stimulated EaRASMCs, as 
analyzed by western blots. Panel A shows a representative blot. Panel B shows fold 
difference in β-actin normalized band intensity for active MMP-2 protein in DOX-NP-
treated EaRASMC layers, relative to control cultures cultured with no NPs (mean ± SD; n 
= 3 cultures/condition). # indicates significant differences versus controls (assigned a value 
of 1.0) deemed for a p value < 0.05.  Panels C-F show effects of unconjugated and cathepsin 
K Ab-conjugated DOX-NPs on MMP-2 and MMP-9 activity in TNF-α activated 
EaRASMCs, as analyzed by gel zymography. Panels C and E show representative images 
of gel zymogram for MMP-2 and MMP-9, respectively. Panels D and F show fold 
difference in β-actin normalized MMP-2 and MMP-9 band intensities compared to NP-
free control cultures, respectively (assigned value of 1.0; dotted line). Values shown 
indicate mean ± SD based on analysis of n = 3 cultures per condition.  # denotes 
significance of differences versus control cultures, deemed for p < 0.05112.  
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4.7. Assessment of αvβ3-Integrin expression in Human Umbilical Vein Endothelial 
Cells (HUVECs) 
 
 In order for the αvβ3-integrin Ab-conjugated NPs to target the integrin in 
endothelial cells, it was crucial to determine the expression of αvβ3-integrin in TNF-α 
stimulated cells compared to unstimulated cells.  The HUVECs were stimulated with TNF-
α for 24 hours prior to IF staining.  In the unstimulated cells (Figure 4.11.A), the expression 
of the αvβ3-integrin is constant across the cell layer with minimal gaps forming between 
cells.  However, compared to the TNF-α stimulated cells (Figure 4.11.B), the αvβ3-
integrin expression is increased along the contact points with other cells and gaps begin to 
form between cells.  The stimulation with TNF-α is expected to have this effect on αvβ3-
integrin expression as this is similar to diseased state cells.  The αvβ3-integrin is involved 
in cell migration and movement, so conjugating the αvβ3-integrin Ab to the NP surface 
will increase the passage of the NPs through the endothelial cell layer to the target SMCs.   
 
Figure 4.11. Expression of αvβ3-integrin in (A) unstimulated HUVECs and (B) TNF-α 
stimulated HUVECs.  The αvβ3-integrin appears green (AF488-tagged secondary 
antibody) and the nuclei appears blue (DAPI).  Expression of the αvβ3-integrin is increased 
when the HUVECs are stimulated with TNF-α.   
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4.8. Assessment of cadherin expression in HUVECs 
 
 Cadherins are a trans-membrane protein that play a vital role in cell-to-cell contact 
and adhesion.  The formation of junctions between cells through cadherins provides the 
necessary binding to keep the endothelium intact.  The disruption of cadherins can be 
caused by cytokine overexpression in diseased states, such as AAA.  For this purpose, 
cadherin expression by ECs was examined in vitro.  HUVECs were untreated (Figure 
4.12.A) or stimulated with TNF-α (Figure 4.12.B) and labeled with the cadherin Ab for 
IF.  The unstimulated HUVECs in Figure 4.12.A show consistent cadherin expression 
along the cell edges and there is minimal gaps between cells.  In the TNF-α stimulated cells 
in Figure 4.12.B, the expression of cadherin around the cell edge decreases and the 
formation of gaps between cells begins to appear.  The formation of gaps between cells is 
significant because this leads to a leaky endothelium similar to the endothelium found in 
AAAs.  The leaky endothelium can be useful in the targeting of the NPs to the AAA due 
to the fact the NPs can pass through the gaps formed between cells and reach the SMCs 
which is crucial in regenerating the elastic matrix.   
 
Figure 4.12. Cadherin expression in HUVECs of unstimulated control cells (A) compared 
to TNF-α stimulated cells (B).  Cadherin appears green (AF488-tagged secondary 
antibody) and the nuclei appears blue (DAPI).  The expression of cadherin decreases 
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following TNF-α stimulation in HUVECs and large micron-sized gaps form between 
cells113.   
 
4.9. Assessment of αvβ3-Integrin Ab incorporation on NP surface 
 
 The conjugation of the αvβ3-integrin Ab to the surface of the NPs was confirmed 
via fluorescent microscopy (Figure 4.13).  In Figure 4.13, unconjugated NPs (A) fluoresce 
red and the αvβ3-Integrin Ab-conjugated NPs with the 488 fluorescent secondary (B) 
fluoresce yellow.  The AF488 secondary antibody fluoresces green but when the red and 
green signals overlap, the fluorescent signal appears yellow.  The overlapping of these 
signals and the yellow fluorescence present in the images confirms the conjugation of the 
αvβ3-Integrin Ab to the NP surface.   
 
Figure 4.13. Microscope images of conjugation of αvβ3-integrin Ab to NP surface.  Panel 
A shows control AF633 NPs without Ab conjugation and Panel B shows the addition of 
the αvβ3-integrin Ab to the NP surface and labelled with a 488 secondary antibody.   
 
4.10. FITC-Dextran migration through a HUVEC layer 
 
 To test the migration of the NPs through the endothelium, it was first decided to 
test the passage of FITC-Dextran through a disrupted HUVEC layer comparable of that in 
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the AAA wall.  The FITC-Dextran used for this experiment was 150 kDa as this size should 
be larger than the NPs used in following experiments.  The FITC-Dextran was allowed to 
migrate through the stimulated and unstimulated HUVECs and the fluorescence was 
measured using a plate reader (Figure 4.14).  The stimulation of HUVECs with TNF-α 
increased the passage of FITC-Dextran through the disrupted cell layer with minimal 
interference from the PET membrane.  This result correlates with the cadherin IF result and 
the gap formation between cells allows for the passage of molecules through the endothelial 
cell layer.  Based on this result, the next step was to determine if the NPs show similar 
migration patterns and if the conjugation with the αvβ3-integrin Ab increases NP passage.   
 
Figure 4.14. The migration of FITC-Dextran was significantly higher through a TNF-α 
stimulated endothelial cell layer compared to an unstimulated cell layer.  The improved 
passage through the cell layer is due to the formation of gaps between the cells. * denotes 
significance of difference, deemed for p < 0.05113. 
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4.11. NP migration through the endothelial cell layer 
 
 Building off the above data, it was necessary to determine the migration of the NPs 
through the HUVEC layer.  HUVECs seeded on membranes containing 1.0 µm pores were 
incubated with αvβ3-integrin Ab-conjugated NPs or with unconjugated NPs and were 
unstimulated or stimulated with TNF-α (Figure 4.15).  The data suggests there is no 
difference between NP migration when the HUVECs were stimulated or unstimulated and 
cultured with unconjugated NPs.  However, the migration of the NPs was slightly lower 
than the blank membrane without cells so the cell layer is preventing the passage of some 
NPs.  Finally, the HUVECs cultured with the αvβ3-integrin Ab-conjugated NPs and 
stimulated with TNF-α showed the greatest migration of NPs through the cell layer.  The 
migration of the conjugated NPs is expected but the migration of the unconjugated NPs 
through the cell layer is greater than expected.  One possible explanation for the migration 
of the unconjugated NPs through the cell layer is the NPs are taken up by the HUVECs 
through endocytosis and are passed through the cell and expelled on the other side.  Another 
possible explanation is the formation of a confluent cell layer and the formation of gaps 
between cells that allow for the NP passage.  To confirm the localization of the NPs in the 
HUVECs, confocal images were taken to identify where NPs were passing through the cell 
layer.   
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Figure 4.15.  Migration of αvβ3-integrin Ab-conjugated NPs and unconjugated NPs 
through the endothelial cell layer.  The modification of the NPs with an αvβ3-integrin Ab 
slightly increased the passage of the NPs through the endothelial cell layer while the 
unconjugated NPs were able to migrate through the cell layer but to a lesser extent. * 
denotes significance of differences versus TNF-α stimulation with αvβ3-integrin Ab-
conjugated NPs, deemed for p< 0.05 
 
4.12. NP localization in the HUVEC layer 
 
 The passage of the NPs through the HUVEC layer was deemed crucial to be able 
to deliver the NPs to SMCs in the medial layer of the aorta.  The previous data has 
demonstrated the ability of the NPs to migrate past endothelial cell layer but it is necessary 
to determine if the NPs are passing through the cells or via the gaps between adjoining 
ECs.  Using AF633-loaded NPs (pseudo-colored green), it was possible to determine the 
localization in the cell layer (Figure 4.16 and Figure 4.17).   
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In Figure 4.16, HUVECs were stimulated with TNF-α and cultured with αvβ3-
integrin Ab-conjugated NPs followed by membrane staining (red) and nucleus staining 
(blue).  Using a confocal microscope, the XY, XZ, and YZ planes were visualized.  Using 
only the XY plane, the location of the NPs cannot be accurately determined.  The NPs 
could be localized on the cell surface but using the XZ and YZ planes, the NPs are located 
within the cell.  The XZ and YZ planes shown in Figure 4.16 are cross sections of the cell 
and confirm the αvβ3-integrin Ab-conjugated NPs are located within the cell.  This is due 
to (1) the NP presence around the nucleus and (2) the appearance of the membrane 
surrounding the NPs.   
 
Figure 4.16. Localization of αvβ3-integrin Ab-conjugated AF633-loaded NPs in HUVECs 
following TNF-α stimulation.  The conjugated NPs are localized within the cell as shown 
in the XZ and YZ axis.  The membrane stain (red) allowed for the location of the NPs to 
be determined.   
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In Figure 4.17, the HUVECs were treated with unconjugated AF633-loaded NPs 
(pseudo-colored green) and the localization of the unconjugated NPs (A) was determined 
and compared to the localization of the αvβ3-integrin Ab-conjugated NPs.  The 
unconjugated NPs location was confirmed by imaging the cell layer at various planes.  The 
image of the cell surface (B) shows minimal fluorescence from the NPs but the images at 
different planes through the cell layer (C) showed an increase in NP fluorescence as the 
plane moved down through the cell.  Another important aspect besides the localization of 
the NPs within the cell, is the localization of the NPs between the cells (D).  The appearance 
of the NPs in the gaps between cells and within the cell regardless of Ab-conjugation 
correlate with previous results.  
 
Figure 4.17. HUVECs treated with unconjugated AF633-loaded NPs (pseudo-colored 
green) (A).  The NP’s location was confirmed by imaging the cell surface (B).  Minimal 
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fluorescence from the NPs was observed at the apical cell surface.  Imaging at different 
planes through the cell layer (C) showed an increase in NP fluorescence as the plane moved 
through the cell.  In addition to NP migration through the cell, the NPs were shown to move 
through the gaps between cells (D)113.   
 
4.13. Effect of DOX-loaded NPs on oxidative stress in HUVECs and EaRASMCs in 
culture 
 
 Induction of oxidative stress and generation of reactive oxygen species (ROS) in 
cultured HUVECs and EaRASMCs by DOX-loaded NPs were evaluated as an affirmative 
outcome could impede the use of NPs for AAA treatment (Figure 4.18).  The DOX-loaded 
NP-treated cultures were compared to untreated cells and a positive and negative control.  
For both the HUVECs and EaRASMCs, the DOX-loaded NPs did not increase the 
oxidative stress compared to the untreated cells and was significantly lower than the 
positive control (Figure 4.18.A).  Similarly for the superoxide assay, the DOX-loaded NPs 
did not increase superoxide production compared to untreated cells (Figure 4.18.B).  This 
result confirms the DOX-loaded NPs, which were used throughout this study, do not induce 
a stress response from either cell type.   
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Figure 4.18. HUVECs and EaRASMCs were exposed to DOX-loaded NPs and no NPs to 
determine the (A) oxidative stress and (B) superoxide production triggered by the NPs.  
The presence of DOX-loaded NPs did not increase oxidative stress or superoxide 
production.  * denotes significance of difference versus positive control, deemed for p < 
0.05. # denotes significance of difference versus negative control, deemed for p < 0.05113. 
 
4.14. Assessing elastase-induced endothelial disruption in whole vessels 
 
 Elastase infusion induced matrix injury within porcine carotid arteries ex vivo was 
used to evoke the AAA.  The elastase breakdowns the extracellular matrix and effectively 
disrupts the endothelial cell layer.  Figure 4.19 shows TEM images of healthy and 
disrupted endothelial cell layers when porcine carotid arteries are treated with elastase.  
Figure 4.19.A and Figure 4.19.C highlights the intact endothelial cell layer of the artery 
following treatment with saline.  The endothelial cells maintain tight junctions as shown in 
Figure 4.19.C.  However, compared to Figure 4.19.B and Figure 4.19.D, the elastase 
treated artery exhibits a denuded endothelium with the basement membrane visibly 
disrupted.  The disruption of the endothelium and basement membrane are consistent with 
abdominal aortic aneurysms suggesting treatment with elastase is a viable option for 
inducing an aneurysm.  Besides the relationship to the aneurysm, the disruption of the 
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endothelium may play a vital role in NP migration and uptake by the AAA.  Previous 
results in this study confirmed NP migration through the endothelial cells and gaps formed 
between cells and the disrupted endothelium and basement membrane following elastase 
treatment provide a large gap for NPs to migrate through.  
 
Figure 4.19. TEM images of (A and C) healthy porcine carotid artery infused with saline 
and (B and D) porcine pancreatic elastase treated porcine carotid artery.  
 
4.15. AAA induction in rat model 
 
 The abdominal aortic aneurysm in the rat model was induced through 
periadventitial elastase treatment.  Figure 4.20.A is a representative image of an aorta prior 
to elastase treatment in a male rat while Figure 4.20.B shows the aorta immediately 
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following elastase treatment.  Immediately following treatment, the aorta changes from a 
red color to a white color indicating damage due to elastase.  In Figure 4.20.C, the same 
aorta is shown following aneurysm development over several weeks.   
 
Figure 4.20. Surgical images of aneurysm induction through periadventitial elastase 
treatment in a rat model.  Panel A shows the exposed aorta prior to elastase treatment and 
Panel B shows the aorta immediately post-treatment.  In Panel C, the aorta is exposed 
following aneurysm development. 
 
 The aneurysm induction surgery was performed on multiple rats (n=3) and images 
were taken prior to treatment and following aneurysm development.  Figure 4.21 shows 
the average diameter of the aorta for three rats following treatment with elastase (1 ml of 
20 units).  The figure shows an increase in aorta diameter for two of the rat models while 
one aorta showed no increase (66.7% success rate).  The increase in diameter was relatively 
small as we intended to achieve, unlike the large AAAs we were able to generate previously 
following elastase infusion/stretch-induced injury110.  In the latter case, the ballooning of 
the aorta upon elastase infusion may allow the elastase to penetrate into the medial layer 
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of the aorta to more effectively disrupt the elastic matrix and hence generate a larger 
aneurysmal expansion.   
 
Figure 4.21. Diameter measurements of rat aorta treated with 1 ml of 20 units of elastase.  
The measurements were obtained from images before elastase treatment and after a 14 day 
aneurysm development period.  * denotes significance of difference compared to pre-
elastase treatment, deemed for p < 0.05. 
 
4.15.1. AAA imaging and measurement using MRI 
 
 The use of MRI allows longitudinal monitoring of aneurysm growth following 
AAA induction surgery in a single animal without need for laparotomy.  Figure 4.22 shows 
multiple MRI scans of the abdominal aorta in a healthy (Figure 4.22.A and Figure 4.22.B) 
and elastase treated rat (Figure 4.22.C and Figure 4.22.D).  Figure 4.22.A shows the aorta 
from below the kidneys to the bifurcation in the lower abdomen and Figure 4.22.B shows 
a 3D rendering of the same aorta.  The 3D rendering provides a clear visual representation 
of the aorta and would allow for localized expansion to be clearly viewed.  Figure 4.22.C 
shows the aorta from the kidneys to the bifurcation in an elastase-injured rat.  Figure 
4.22.D is a 3D rendering of the aorta and the image has been rotated 30°.  The rendering 
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enables visualization of the aorta from multiple angles so if the localized expansion is not 
in the coronal plane, it can be seen in another plane.  An example of a small expansion can 
be seen in Figure 4.22.D highlighted by the red box.  Though the purpose of these initial 
MRI imaging protocols was to merely optimize imaging parameters for reliable assessment 
of aneurysm/aorta size and spatiotemporal differences in the same rat, which is still 
ongoing, our initial imaging outcomes at the very least however, demonstrate our success 
in generating early aneurysmal expansions which exhibit significant spatial anisotropy.   
  
 
Figure 4.22.  MRI scans of a healthy (A, B) and elastase treated (C, D) aorta in a rat model. 
The healthy rat aorta (A) was clearly shown in the MRI scan and this enabled diameter 
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measurements.  Using the same aorta, a 3D rendering (B) was generated which allows for 
further visualization of the aorta.  The elastase treated aorta (C) was visualized using the 
same protocol as the healthy aorta.  The elastase injured aorta was 3D rendered (D) to 
visualize any expansions from treatment.     
 
4.15.2. NP localization in rat AAA model 
 
 Preliminary in vivo infusion studies were performed on VivoTag 800® loaded 
cathepsin K Ab-conjugated NPs.  The expression of cathepsin K in the elastase-injured rat 
AAA model was increased compared to the healthy aorta (Figure 4.23).  The expression 
of cathepsin K in the aorta will be the target for the cathepsin K-Ab conjugated NPs.  The 
cathepsin K Ab-conjugated NPs were injected via tail vein injection and allowed to 
circulate for 1 or 3 hours.  The rat was euthanized and the aorta imaged using an IVIS 
Spectrum CT whole tissue imager.  Preliminary results (Figure 4.24 and Figure 4.25) 
show localization of the NPs within the aortal segment in the abdomen.  Figure 4.24.A 
shows the exposed aorta with the cathepsin K Ab-conjugated NPs (pseudo-colored blue) 
localized.  Figure 4.24.B and Figure 4.24.C are control images in which the injection site 
of the cathepsin K Ab-conjugated NPs is visible due to the NPs present (B) and the residual 
NPs visualized in the vial (C).  These results are promising as preliminary data and further 
investigation is warranted.  The biodistribution (Figure 4.25) was determined using similar 
imaging methods with images of the chest cavity (Figure 4.25.A and Figure 4.25.B) and 
the abdominal cavity (Figure 4.25.C and Figure 4.25.D) to determine the location of NPs.  
The preliminary data shows the localization of the NPs in the abdominal aorta and the chest 
cavity.  However, longer term NP biodistribution, retention, and safety studies need to be 
performed as a function of NP dose and time in AAA-induced rats, which have been 
initiated.   
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Figure 4.23.  Relative expression of cathepsin K in healthy and elastase injured rat AAA 
models.  The plot shows β-actin normalized cathepsin K band intensity (n = 3 per case). 
 
 
Figure 4.24. Preliminary results of cathepsin K Ab-conjugated VivoTag 800®-loaded NP 
localization in an AAA rat model.  (A) The exposed aorta of the rat following tail vein 
injection of the NPs.  (B) The injection site of the NPs visible 1 hour post injection.  (C) 
The residual NPs in the vial as a control for NP fluorescence.  NPs are pseudo-colored blue.  
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Figure 4.25.  Biodistribution of VivoTag 800®-loaded NPs in elastase-injured rat AAA 
model 3 hours post-injection.  The fluorescent image of the chest (A) show fluorescence 
from the NPs while (B) shows the organs imaged.  The fluorescence of the abdominal 
cavity (C) shows fluorescence from the NPs and (D) shows the aorta and other organs 
imaged.     
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CHAPTER V 
CONCLUSIONS AND RECOMMENDATIONS 
 
5.1. Conclusions 
 
 The goal of this study was to investigate cathepsin K Ab surface functionalization 
of our matrix regenerative DOX NPs as an effective means of targeting them to the AAA 
wall following a simple intravenous infusion protocol. Towards rationalizing and guiding 
rigorous studies to investigate the biodistribution, safety and therapeutic efficacy of these 
nanoformulations in a pre-clinical rat model of elastase-induced AAAs, this study has 
successfully fulfilled the sub-aims of a) demonstrating cathepsin K as a viable target for 
homing in NPs to the AAA wall, b) showing that cathepsin K Abs can be stably 
functionalized on the polymer NP surface with no adverse implications to their physical 
properties and beneficial pro-elastic matrix regenerative (i.e., increased elastic matrix 
synthesis, crosslinking, fiber formation) and anti-proteolytic effects, and to cellular health, 
and c) generating evidence supporting trans-endothelial transport of the NPs from the AAA 
vessel lumen to the underlying disrupted aortal medial layer. More specifically, our study 
generated the following findings: 
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 Cathepsin K expression is significantly increased in EaRASMCs when stimulated by 
TNF-α, a cytokine known to be over-expressed in the AAA wall. Cathepsin K 
expression is primarily localized on the cell membrane which can be readily accessed 
by NPs.  
 Elastase-induced vessel injury, our model to generate AAAs, triggers significant 
increases in cathepsin K expression in the vessel wall, both ex vivo (in porcine 
carotids) and in vivo (rat model), likely associated with increased expression of the 
enzyme by aneurysmal SMCs as described above. 
 Covalent conjugation results in efficient and stable functionalization of the NP surface 
with the cathepsin K Ab, with no significant changes to NP size, charge, DOX release, 
and the pro-elastic fiber neoassembly-augmenting and anti-MMP effects attributed to 
the cationic amphiphile-surface modified PLGA nanocarrier and released active 
agent, DOX. In addition, the NPs at the doses deemed appropriate to deliver the useful 
DOX dosing level do not incite oxidative stress or generation of reactive oxygen 
species in cultured EaRASMCs and HUVECs. 
 Elastase-induced vessel injury, and associated TNF- overexpression have been 
separately shown to cause activation and disruption/denudation of an intact 
endothelial layer as demonstrated within the vessel wall and in HUVEC cultures 
respectively. Where retained, the ECs lose expression of their cadherin junctions that 
maintain contact between adjacent cells to develop microns-sized gaps between, and 
also exhibit upregulated expression of αvβ3-integrins along their periphery.  
 Cathepsin K Ab-conjugated NPs are able to migrate across a disrupted endothelial 
layer by both passive diffusion through inter-endothelial gaps, and by trans-cytosis. 
111 
 
In addition, αvβ3 Ab-modification of the NP surface provides additional opportunities 
in the future to augment endothelial binding and trans-endothelial transport of the NPs, 
although passive transport, in the absence of such targeting is itself significant. 
 Initial in vivo infusion of VivoTag 800® cathepsin K Ab-conjugated NPs via the IV 
route indicated localization of the NPs in the abdominal aneurysm segment, with some 
additional fluorescence detected in the chest cavity, likely the lung. This promising 
data suggests effective but likely inefficient targeting of the NPs to the AAA wall 
using this modality.  
5.2. Limitations and recommendations 
 
 Below we list key limitations of the experiments as conducted and 
recommendations for future follow-up investigations.   
 The use of elastase for aneurysm induction provides a reproducible and effective 
mode for aorta disruption.  However, in our experience as with that previously 
reported only ~66% of animals develop an aneurysm following periadventitial or 
infusion based aortal tissue injury.  However, the infusion/vessel ballooning 
method allows elastase to penetrate between the stretched elastic lamellae causing 
more effective mechanical disruption of the wall structure compared to 
periadventitial elastase treatment, which in turn may enhance aneurysm formation 
and size.  The technical skills required for elastase infusion are much greater than 
the elastase treatment but may produce a larger number of aneurysms in the rat 
models.  While we have pursued the former method in this study for the purpose of 
simplicity, future in vivo studies will involve intraluminal elastase infusion which 
we had shown effective in a prior study110. 
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 The use of the VivoTag 800®-loaded NPs enabled the visualization of the NPs in 
the rat AAA model.  However, the rat had to be euthanized to allow for the aorta to 
be visualized.  This was a significant limitation as several rat models would be 
needed for each time point for multiple time points.  This would require a large 
number of animals as well as significant surgery time.  To visualize the NPs without 
euthanizing, the NPs could be loaded with paramagnetic iron oxide NPs (SPIONs).  
We have recently published findings that show SPIONs to impart magnetic 
mobility to the DOX-NPs in an applied magnetic field and to not alter their physical 
or biological effects. The SPION-DOX NPs could then be conjugated with the 
cathepsin K Ab and injected via the tail vein or even better within the flow occluded 
AAA segment using a balloon drug delivery catheter and guided to the AAA wall 
by application of a preclinical MRI-generated external magnetic driving force.  The 
NPs driven to the AAA wall in this manner would then ‘stick’ to the EaRASMC 
surface.  The dual modality of active targeting of NPs could circumvent the 
otherwise unavoidable passage and removal of IV-infused NPs in the lungs en route 
to the aorta.  SPIONs within the DOX-NPs can also help track their in vivo retention 
and biodistribution using MRI.    
 Further investigation in the biodistribution of the cathepsin K Ab-conjugated NPs 
following tail vein injection is warranted.  Preliminary data was collected in this 
study and was promising but additional data is necessary to confirm the targeting, 
retention and biodistribution of the NPs.  The concentration of cathepsin K Ab-
conjugated NPs injected was 10 mg/ml which was enough to produce fluorescence 
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in the rat model.  However, this concentration may not be optimal to visualize 
localization as too much or too little could significantly affect the results.  
 Finally, once the biodistribution of the NPs has been determined and the NPs can 
be localized to the AAA, the pro-elastogenic effects and anti-proteolytic effects of 
the DOX-loaded NPs will be examined in vivo.   
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